1
|
Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C, Engels K, Rezai M, Jackisch C, Schmitt WD, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching PA, Weber K, Rhiem K, Denkert C, Schneeweiss A. Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]. Ann Oncol 2022; 33:743-744. [PMID: 35595658 DOI: 10.1016/j.annonc.2022.04.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Affiliation(s)
- S Loibl
- German Breast Group, Neu-Isenburg; Oncological Practice Bethanien, Cancer Center Frankfurt Northeast, Frankfurt am Main.
| | - M Untch
- HELIOS Klinikum Berlin-Buch, Berlin
| | | | - J Huober
- Brustzentrum, Universitätsfrauenklinik Ulm, Ulm
| | - B V Sinn
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin; Berlin Institute of Health (BIH), Berlin
| | - J-U Blohmer
- Gynäkologie mit Brustzentrum, Charité-Universitätsmedizin Berlin, Berlin
| | | | | | - H Tesch
- Oncological Practice Bethanien, Cancer Center Frankfurt Northeast, Frankfurt am Main
| | - C Hanusch
- Rotkreuzklinikum München Frauenklinik, München
| | - K Engels
- Zentrum für Pathologie, Zytologie und Molekularpathologie Neuss, Neuss
| | - M Rezai
- Medical Center, Luisenkrankenhaus Düsseldorf, Düsseldorf
| | - C Jackisch
- Brustzentrum, Sana-Klinikum Offenbach, Offenbach
| | - W D Schmitt
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin
| | | | - J Thomalla
- Praxisklinik für Hämatologie und Onkologie Koblenz, Koblenz
| | - S Kümmel
- Breast Unit, Kliniken Essen-Mitte, Essen
| | - B Rautenberg
- Klinik für Frauenheilkunde, Universitätsklinikum Freiburg, Freiburg
| | - P A Fasching
- Brustzentrum, Universitätsklinikum Erlangen, Erlangen
| | - K Weber
- German Breast Group, Neu-Isenburg
| | - K Rhiem
- Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Cologne
| | - C Denkert
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin
| | - A Schneeweiss
- National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany
| |
Collapse
|
2
|
Lozzi Da Costa I, Sinn B, Arnold A, Andreou A, Felsenstein M, Schirmeier A, Reutzel-Selke A, Pratschke J, Sauer I, Feist M. 177P TP53 and PRBM1 mutations predict “hot” tumor microenvironment in intrahepatic cholangiocarcinoima. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
3
|
Vladimirova V, Schneeweiss A, Jackisch C, Weber K, Denkert C, Schmatloch S, Karn T, Fasching P, Braun S, Szeto C, Sinn B, van Mackelenbergh M, Schem C, Stickeler E, Soon-Shiong P, Marmé F, Mueller V, Untch M, Nekljudova V, Loibl S. 21P BACH1 and HIF1α predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
4
|
Leichsenring J, Vladimirova V, Solbach C, Karn T, Ataseven B, Sinn B, Barinoff J, Mueller V, Blohmer JU, Schem C, Engels K, Marmé F, Fissler-Eckhoff A, Fasching P, Stickeler E, van Mackelenbergh M, Denkert C, Stenzinger A, Loibl S, Gröschel S. 28P EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
5
|
Furlanetto J, Denkert C, Untch M, Sinn B, Lederer B, Schneeweiss A, Mueller V, van Mackelenbergh M, Stickeler E, Fasching P, Schem C, Karn T, Marmé F, Nekljudova V, Loibl S. 17P Impact of body mass index (BMI) on prognostic and predictive value of stromal tumour-infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC): A pooled analysis of six neoadjuvant trials. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
6
|
Denkert C, Untch M, Benz S, Schneeweiss A, Weber KE, Schmatloch S, Jackisch C, Sinn HP, Golovato J, Karn T, Marmé F, Link T, Budczies J, Nekljudova V, Schmitt WD, Stickeler E, Müller V, Jank P, Parulkar R, Heinmöller E, Sanborn JZ, Schem C, Sinn BV, Soon-Shiong P, van Mackelenbergh M, Fasching PA, Rabizadeh S, Loibl S. Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy ⋆. Ann Oncol 2021; 32:500-511. [PMID: 33418062 DOI: 10.1016/j.annonc.2020.12.016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2020] [Revised: 11/13/2020] [Accepted: 12/20/2020] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND Different endogenous and exogenous mutational processes act over the evolutionary history of a malignant tumor, driven by abnormal DNA editing, mutagens or age-related DNA alterations, among others, to generate the specific mutational landscape of each individual tumor. The signatures of these mutational processes can be identified in large genomic datasets. We investigated the hypothesis that genomic patterns of mutational signatures are associated with the clinical behavior of breast cancer, in particular chemotherapy response and survival, with a particular focus on therapy-resistant disease. PATIENTS AND METHODS Whole exome sequencing was carried out in 405 pretherapeutic samples from the prospective neoadjuvant multicenter GeparSepto study. We analyzed 11 mutational signatures including biological processes such as APOBEC-mutagenesis, homologous recombination deficiency (HRD), mismatch repair deficiency and also age-related or tobacco-induced alterations. RESULTS Different subgroups of breast carcinomas were defined mainly by differences in HRD-related and APOBEC-related mutational signatures and significant differences between hormone-receptor (HR)-negative and HR-positive tumors as well as correlations with age, Ki-67 and immunological parameters were observed. We could identify mutational processes that were linked to increased pathological complete response rates to neoadjuvant chemotherapy with high significance. In univariate analyses for HR-positive tumors signatures, S3 (HRD, P < 0.001) and S13 (APOBEC, P = 0.001) as well as exonic mutation rate (P = 0.002) were significantly correlated with increased pathological complete response rates. The signatures S3 (HRD, P = 0.006) and S4 (tobacco, P = 0.011) were prognostic for reduced disease-free survival of patients with chemotherapy-resistant tumors. CONCLUSION The results of this investigation suggest that the clinical behavior of a tumor, in particular, response to neoadjuvant chemotherapy and disease-free survival of therapy-resistant tumors, could be predicted by the composition of mutational signatures as an indicator of the individual genomic history of a tumor. After additional validations, mutational signatures might be used to identify tumors with an increased response rate to neoadjuvant chemotherapy and to define therapy-resistant subgroups for future therapeutic interventions.
Collapse
Affiliation(s)
- C Denkert
- Institute of Pathology, Philipps-University Marburg and University Hospital Marburg (UK-GM), Marburg, Germany; Charité - Universitätsmedizin Berlin, Institute of Pathology, Berlin, Germany.
| | - M Untch
- Helios Klinikum Berlin-Buch, Department of Obstetrics and Gynaecology, Berlin, Germany
| | - S Benz
- NantOmics, LLC, Culver City, USA
| | - A Schneeweiss
- Nationales Centrum für Tumorerkrankungen, Universitätsklinikum und Deutsches Krebsforschungszentrum Heidelberg, Heidelberg, Germany
| | - K E Weber
- German Breast Group (GBG), Neu-Isenburg, Germany
| | - S Schmatloch
- Brustzentrum Kassel, Elisabeth Krankenhaus, Kassel, Germany
| | - C Jackisch
- Department of Obstetrics and Gynecology and Breast Cancer Center, Sana Klinikum Offenbach, Offenbach, Germany
| | - H P Sinn
- Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; German Cancer consortium (DKTK), Heidelberg, Germany
| | | | - T Karn
- Klinik für Frauenheilkunde und Geburtshilfe, Goethe Universität, Frankfurt, Germany
| | - F Marmé
- Universitätsfrauenklinik Mannheim, Mannheim, Germany
| | - T Link
- Department of Gynecology and Obstetrics, Technische Universität Dresden, Dresden, Germany
| | - J Budczies
- Charité - Universitätsmedizin Berlin, Institute of Pathology, Berlin, Germany; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; German Cancer consortium (DKTK), Heidelberg, Germany
| | - V Nekljudova
- German Breast Group (GBG), Neu-Isenburg, Germany
| | - W D Schmitt
- Charité - Universitätsmedizin Berlin, Institute of Pathology, Berlin, Germany
| | - E Stickeler
- Department of Gynecology, RWTH Aachen, Aachen, Germany
| | - V Müller
- Department of Gynecology, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
| | - P Jank
- Institute of Pathology, Philipps-University Marburg and University Hospital Marburg (UK-GM), Marburg, Germany; Charité - Universitätsmedizin Berlin, Institute of Pathology, Berlin, Germany
| | | | | | | | - C Schem
- Mammazentrum Hamburg am Krankenhaus Jerusalem, Hamburg, Germany
| | - B V Sinn
- Charité - Universitätsmedizin Berlin, Institute of Pathology, Berlin, Germany
| | | | - M van Mackelenbergh
- Universitätsklinikum Schleswig-Holstein, Klinik für Gynäkologie und Geburtshilfe, Kiel, Germany
| | - P A Fasching
- Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | | | - S Loibl
- German Breast Group (GBG), Neu-Isenburg, Germany; University of Frankfurt, Frankfurt am Main, Germany
| |
Collapse
|
7
|
Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C, Engels K, Rezai M, Jackisch C, Schmitt WD, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching PA, Weber K, Rhiem K, Denkert C, Schneeweiss A. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol 2020; 30:1279-1288. [PMID: 31095287 DOI: 10.1093/annonc/mdz158] [Citation(s) in RCA: 387] [Impact Index Per Article: 96.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Combining immune-checkpoint inhibitors with chemotherapy yielded an increased response rates in patients with metastatic triple-negative breast cancer (TNBC). Therefore, we evaluated the addition of durvalumab to standard neoadjuvant chemotherapy (NACT) in primary TNBC. PATIENTS AND METHODS GeparNuevo is a randomised phase II double-blind placebo-controlled study randomising patients with TNBC to durvalumab or placebo given every 4 weeks in addition to nab-paclitaxel followed by standard EC. In the window-phase durvalumab/placebo alone was given 2 weeks before start of nab-paclitaxel. Randomisation was stratified by stromal tumour-infiltrating lymphocyte (sTILs). Patients with primary cT1b-cT4a-d disease, centrally confirmed TNBC and sTILs were included. Primary objective was pathological complete response (pCR) (ypT0 ypN0). RESULTS A total of 174 patients were randomised, 117 participated in the window-phase. Median age was 49.5 years (range 23-76); 47 patients (27%) were younger than 40 years; 113 (65%) had stage ≥IIA disease, 25 (14%) high sTILs, 138 of 158 (87%) were PD-L1-positive. pCR rate with durvalumab was 53.4% (95% CI 42.5% to 61.4%) versus placebo 44.2% (95% CI 33.5% to 55.3%; unadjusted continuity corrected χ2P = 0.287), corresponding to OR = 1.45 (95% CI 0.80-2.63, unadjusted Wald P = 0.224). Durvalumab effect was seen only in the window cohort (pCR 61.0% versus 41.4%, OR = 2.22, 95% CI 1.06-4.64, P = 0.035; interaction P = 0.048). In both arms, significantly increased pCR (P < 0.01) were observed with higher sTILs. There was a trend for increased pCR rates in PD-L1-positive tumours, which was significant for PD-L1-tumour cell in durvalumab (P = 0.045) and for PD-L1-immune cell in placebo arm (P = 0.040). The most common immune-related adverse events were thyroid dysfunction any grade in 47%. CONCLUSIONS Our results suggest that the addition of durvalumab to anthracycline-/taxane-based NACT increases pCR rate particularly in patients treated with durvalumab alone before start of chemotherapy. TRIAL REGISTRATION ClinicalTrials.gov number: NCT02685059.
Collapse
Affiliation(s)
- S Loibl
- German Breast Group, Neu-Isenburg; Oncological Practice Bethanien, Cancer Center Frankfurt Northeast, Frankfurt am Main.
| | - M Untch
- HELIOS Klinikum Berlin-Buch, Berlin
| | | | - J Huober
- Brustzentrum, Universitätsfrauenklinik Ulm, Ulm
| | - B V Sinn
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin; Berlin Institute of Health (BIH), Berlin
| | - J-U Blohmer
- Gynäkologie mit Brustzentrum, Charité-Universitätsmedizin Berlin, Berlin
| | | | | | - H Tesch
- Oncological Practice Bethanien, Cancer Center Frankfurt Northeast, Frankfurt am Main
| | - C Hanusch
- Rotkreuzklinikum München Frauenklinik, München
| | - K Engels
- Zentrum für Pathologie, Zytologie und Molekularpathologie Neuss, Neuss
| | - M Rezai
- Medical Center, Luisenkrankenhaus Düsseldorf, Düsseldorf
| | - C Jackisch
- Brustzentrum, Sana-Klinikum Offenbach, Offenbach
| | - W D Schmitt
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin
| | | | - J Thomalla
- Praxisklinik für Hämatologie und Onkologie Koblenz, Koblenz
| | - S Kümmel
- Breast Unit, Kliniken Essen-Mitte, Essen
| | - B Rautenberg
- Klinik für Frauenheilkunde, Universitätsklinikum Freiburg, Freiburg
| | - P A Fasching
- Brustzentrum, Universitätsklinikum Erlangen, Erlangen
| | - K Weber
- German Breast Group, Neu-Isenburg
| | - K Rhiem
- Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Cologne
| | - C Denkert
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin
| | - A Schneeweiss
- National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany
| |
Collapse
|
8
|
Karn T, Denkert C, Sinn BV, Weber K, Nekljudova V, Rody A, Meissner T, Hatzis C, El-Balat A, Becker S, Solbach C, Untch M, Schneeweiss A, von Minckwitz G, Loibl S, Pusztai L, Holtrich U. Abstract P3-10-01: Single-cell profiling identifies hypoxic carcinoma cells as source of an immunosuppressive VEGFA metagene. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-10-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
We have previously shown that expression of the IL8/VEGFA-metagene eliminates the good prognostic effect of TILs in TNBC (PMID 21978456, 28750120). We also showed that the VEGFA metagene predicted response to neoadjuvant bevacizumab in the GeparQuinto trial (Karn 2017 SABCS #851166). The main cellular sources of the transcripts that comprise the VEGFA metagene are unknown since mRNA profiling of bulk biopsies contains signals from different cell types.
Methods:
Individual genes that comprise the VEGFA metagene were measured in bulk tissue- and single cell-RNA-Seq from breast cancer subtypes and normal cells on different platforms (Affymetrix n=4915, Agilent n=597, Illumina n=2433, RNA-Seq n=1215, Exome Capture RNA-Seq n=226, HTG-Seq n=243, sc-RNA-Seq n=24710). For blinded, orthogonal validation we performed immunohistochemistry. Effect of neoadjuvant chemotherapy with or without bevacizumab was studied by RNA-Seq and IHC on samples from GeparQuinto trial. SWOG S0800 (GSE114403), PROMIX (GSE87455), and GeparSixto trials were used for validation. TCGA was mined for mutations and somatic CNA. RNA-Seq from GeparNuevo was used for correlation with checkpoint inhibitor treatment.
Results:
We identified a stable core of six genes (VEGFA, ANGPTL4, ADM, NDRG1, DDIT4, CSTB) in different cohorts. Strong expression of this signature was mainly restricted to TNBC subtype and associated with poor prognosis within this subgroup. Single cell RNA-Seq of breast epithelial cells from 4 reduction mammoplasties and 4 TNBC revealed that these genes are coexpressed in individual epithelial cells and not associated with endothelial cells. In line with their presumed functions in cellular stress and hypoxia, immunohistochemistry revealed strong para-necrotic expression in TNBC. Moreover, high gene expression in TNBC was associated with mutations in DNA damage control pathways, somatic copy number alterations, and lower TILs. While chemotherapy led to downregulation, bevacizumab increased expression. In multivariate analysis, high pretreatment values predict pCR to both bevacizumab and chemotherapy (OR 2.40, P=0.006), which may be explained by sensitivity of tumors which are already under cellular stress. On the other hand, expression of the VEGFA metagene seems to create an immunosuppressive environment that counteracts the positive prognostic effect of TILs. In pre-treatment biopsies from the GeparNuevo checkpoint inhibitor trial we found a negative correlation of VEGFA metagene expression with the amount of the recently identified tissue-resident memory T cell subset (CD8TRM, PMID 29942092; P=0.002), while the subsequent increase of CD8TRM during treatment was larger in tumors with high VEGFA (P=0.019).
Conclusions:
Perinecrotic carcinoma cells under stress from hypoxia and or chromosomal instability are the source of the VEGFA metagene signature. Its predictive value in TNBC suggests estimating and reporting the amount of necrosis in the pathology report may be helpful in predicting response to preoperative chemotherapy, and could be used as stratification factor in clinical trials. The signature indicates an immunosuppressive environment and should be further studied in the context of immune therapies in combinations with anti-angiogenic treatment.
Citation Format: Karn T, Denkert C, Sinn BV, Weber K, Nekljudova V, Rody A, Meissner T, Hatzis C, El-Balat A, Becker S, Solbach C, Untch M, Schneeweiss A, von Minckwitz G, Loibl S, Pusztai L, Holtrich U. Single-cell profiling identifies hypoxic carcinoma cells as source of an immunosuppressive VEGFA metagene [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-10-01.
Collapse
Affiliation(s)
- T Karn
- Goethe University, Frankfurt, Germany; Charite University, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; University Hospital Schleswig-Holstein, Lübeck, Germany; Avera Cancer Institute, Sioux Falls, SD; Yale Cancer Center, New Haven, CT; Helios Kliniken, Berlin-Buch, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - C Denkert
- Goethe University, Frankfurt, Germany; Charite University, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; University Hospital Schleswig-Holstein, Lübeck, Germany; Avera Cancer Institute, Sioux Falls, SD; Yale Cancer Center, New Haven, CT; Helios Kliniken, Berlin-Buch, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - BV Sinn
- Goethe University, Frankfurt, Germany; Charite University, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; University Hospital Schleswig-Holstein, Lübeck, Germany; Avera Cancer Institute, Sioux Falls, SD; Yale Cancer Center, New Haven, CT; Helios Kliniken, Berlin-Buch, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - K Weber
- Goethe University, Frankfurt, Germany; Charite University, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; University Hospital Schleswig-Holstein, Lübeck, Germany; Avera Cancer Institute, Sioux Falls, SD; Yale Cancer Center, New Haven, CT; Helios Kliniken, Berlin-Buch, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - V Nekljudova
- Goethe University, Frankfurt, Germany; Charite University, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; University Hospital Schleswig-Holstein, Lübeck, Germany; Avera Cancer Institute, Sioux Falls, SD; Yale Cancer Center, New Haven, CT; Helios Kliniken, Berlin-Buch, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - A Rody
- Goethe University, Frankfurt, Germany; Charite University, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; University Hospital Schleswig-Holstein, Lübeck, Germany; Avera Cancer Institute, Sioux Falls, SD; Yale Cancer Center, New Haven, CT; Helios Kliniken, Berlin-Buch, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - T Meissner
- Goethe University, Frankfurt, Germany; Charite University, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; University Hospital Schleswig-Holstein, Lübeck, Germany; Avera Cancer Institute, Sioux Falls, SD; Yale Cancer Center, New Haven, CT; Helios Kliniken, Berlin-Buch, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - C Hatzis
- Goethe University, Frankfurt, Germany; Charite University, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; University Hospital Schleswig-Holstein, Lübeck, Germany; Avera Cancer Institute, Sioux Falls, SD; Yale Cancer Center, New Haven, CT; Helios Kliniken, Berlin-Buch, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - A El-Balat
- Goethe University, Frankfurt, Germany; Charite University, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; University Hospital Schleswig-Holstein, Lübeck, Germany; Avera Cancer Institute, Sioux Falls, SD; Yale Cancer Center, New Haven, CT; Helios Kliniken, Berlin-Buch, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - S Becker
- Goethe University, Frankfurt, Germany; Charite University, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; University Hospital Schleswig-Holstein, Lübeck, Germany; Avera Cancer Institute, Sioux Falls, SD; Yale Cancer Center, New Haven, CT; Helios Kliniken, Berlin-Buch, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - C Solbach
- Goethe University, Frankfurt, Germany; Charite University, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; University Hospital Schleswig-Holstein, Lübeck, Germany; Avera Cancer Institute, Sioux Falls, SD; Yale Cancer Center, New Haven, CT; Helios Kliniken, Berlin-Buch, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - M Untch
- Goethe University, Frankfurt, Germany; Charite University, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; University Hospital Schleswig-Holstein, Lübeck, Germany; Avera Cancer Institute, Sioux Falls, SD; Yale Cancer Center, New Haven, CT; Helios Kliniken, Berlin-Buch, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - A Schneeweiss
- Goethe University, Frankfurt, Germany; Charite University, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; University Hospital Schleswig-Holstein, Lübeck, Germany; Avera Cancer Institute, Sioux Falls, SD; Yale Cancer Center, New Haven, CT; Helios Kliniken, Berlin-Buch, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - G von Minckwitz
- Goethe University, Frankfurt, Germany; Charite University, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; University Hospital Schleswig-Holstein, Lübeck, Germany; Avera Cancer Institute, Sioux Falls, SD; Yale Cancer Center, New Haven, CT; Helios Kliniken, Berlin-Buch, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - S Loibl
- Goethe University, Frankfurt, Germany; Charite University, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; University Hospital Schleswig-Holstein, Lübeck, Germany; Avera Cancer Institute, Sioux Falls, SD; Yale Cancer Center, New Haven, CT; Helios Kliniken, Berlin-Buch, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - L Pusztai
- Goethe University, Frankfurt, Germany; Charite University, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; University Hospital Schleswig-Holstein, Lübeck, Germany; Avera Cancer Institute, Sioux Falls, SD; Yale Cancer Center, New Haven, CT; Helios Kliniken, Berlin-Buch, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - U Holtrich
- Goethe University, Frankfurt, Germany; Charite University, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; University Hospital Schleswig-Holstein, Lübeck, Germany; Avera Cancer Institute, Sioux Falls, SD; Yale Cancer Center, New Haven, CT; Helios Kliniken, Berlin-Buch, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| |
Collapse
|
9
|
Seiler S, Schmatloch S, Reinisch M, Neunhöffer T, Schmidt M, Bechtner C, Marmé F, Wagner M, Möbus V, Reimer T, Kleine-Tebbe A, Sinn B, Stickeler E, Untch M, Janni W, Seither F, Loibl S. Abstract P1-17-07: Cancer management and outcome of very young non-pregnant patients with breast cancer diagnosed at 40 years or younger– GBG 29. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-17-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
Breast cancer diagnosed in young women who are 40 years (yrs) or younger is a relatively rare disease. However, it represents the most common cause of cancer-related deaths in this age-group. Furthermore, young age at diagnosis is associated with an increased risk of recurrence and worse survival. To date, general concepts concerning oncological cancer management should be driven by clinicopathological tumor characteristics and should adhere to standardized protocols for patients in general, but little is known about the oncological cancer treatment and outcome of this very young women in today's clinical practice.
Patients and Methods
The breast cancer in pregnancy registry study (BCP/GBG29/BIG 03-02) is a multicenter, international, observational study. BCP was established to investigate the oncological management and outcome of breast cancer in pregnancy. Since 2014 non-pregnant patients who are 40 yrs or younger are eligible if diagnosed with histological confirmed invasive breast cancer, independent of the type of treatment as control cohort. All patients received oncological treatment according to local standards. In this study the following endpoints will be analyzed descriptively for the young non-pregnant women cohort: breast cancer staging at diagnosis, biological characteristics of breast cancer at diagnosis, diagnostic procedures, treatment modalities, toxicity, pathological complete response after neoadjuvant chemotherapy, disease-free survival and overall survival.
Results
From February 2014 until June 2018, 969 non-pregnant patients ≤40 yrs have been registered. The median age at diagnosis was 35 yrs (range 19-40). Overall, 90.1% of patients had a stage T1-2 at diagnosis and 67.1% of patients had negative lymph nodes. 86.7% of tumors were invasive ductal carcinomas and 4.1% lobular carcinomas. Grading (G) 3 was reported in 55.5%. 26.6% of tumors were luminal A-like (ER- and/or PgR-positive, HER2-negative, G1-2), 40.0% luminal B-like (ER- and/or PgR-positive, HER2-negative, G3 or ER- and/or PgR-positive, HER2-positive, any G), 7.7% HER2 positive non-luminal-like, and 25.7% triple negative breast cancers. 3.8% of young non-pregnant patients had metastatic disease at primary diagnosis.
Conclusion
This registry comprises a large cohort of young non-pregnant patients with breast cancer diagnosed at the age of 40 yrs or younger and provides important data about a modern breast cancer treatment as well as oncological outcome in this setting of young women. Further results including oncological management, toxicity, and survival will be presented at the meeting.
Citation Format: Seiler S, Schmatloch S, Reinisch M, Neunhöffer T, Schmidt M, Bechtner C, Marmé F, Wagner M, Möbus V, Reimer T, Kleine-Tebbe A, Sinn B, Stickeler E, Untch M, Janni W, Seither F, Loibl S. Cancer management and outcome of very young non-pregnant patients with breast cancer diagnosed at 40 years or younger– GBG 29 [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-17-07.
Collapse
Affiliation(s)
- S Seiler
- German Breast Group, Neu-Isenburg, Germany; Brustzentrum, Elisabeth Krankenhaus, Kassel, Germany; Brustzentrum, Kliniken Essen-Mitte, Essen, Germany; HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Universitätsmedizin Mainz, Mainz, Germany; Brustzentrum, Klinikum Memmingen, Memmingen, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Siloah St. Trudpert Klinikum, Pforzheim, Germany; Klinikum für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock, Rostock, Germany; Brustzentrum, DRK Kliniken, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Freiburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Ulm, Germany
| | - S Schmatloch
- German Breast Group, Neu-Isenburg, Germany; Brustzentrum, Elisabeth Krankenhaus, Kassel, Germany; Brustzentrum, Kliniken Essen-Mitte, Essen, Germany; HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Universitätsmedizin Mainz, Mainz, Germany; Brustzentrum, Klinikum Memmingen, Memmingen, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Siloah St. Trudpert Klinikum, Pforzheim, Germany; Klinikum für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock, Rostock, Germany; Brustzentrum, DRK Kliniken, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Freiburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Ulm, Germany
| | - M Reinisch
- German Breast Group, Neu-Isenburg, Germany; Brustzentrum, Elisabeth Krankenhaus, Kassel, Germany; Brustzentrum, Kliniken Essen-Mitte, Essen, Germany; HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Universitätsmedizin Mainz, Mainz, Germany; Brustzentrum, Klinikum Memmingen, Memmingen, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Siloah St. Trudpert Klinikum, Pforzheim, Germany; Klinikum für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock, Rostock, Germany; Brustzentrum, DRK Kliniken, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Freiburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Ulm, Germany
| | - T Neunhöffer
- German Breast Group, Neu-Isenburg, Germany; Brustzentrum, Elisabeth Krankenhaus, Kassel, Germany; Brustzentrum, Kliniken Essen-Mitte, Essen, Germany; HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Universitätsmedizin Mainz, Mainz, Germany; Brustzentrum, Klinikum Memmingen, Memmingen, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Siloah St. Trudpert Klinikum, Pforzheim, Germany; Klinikum für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock, Rostock, Germany; Brustzentrum, DRK Kliniken, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Freiburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Ulm, Germany
| | - M Schmidt
- German Breast Group, Neu-Isenburg, Germany; Brustzentrum, Elisabeth Krankenhaus, Kassel, Germany; Brustzentrum, Kliniken Essen-Mitte, Essen, Germany; HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Universitätsmedizin Mainz, Mainz, Germany; Brustzentrum, Klinikum Memmingen, Memmingen, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Siloah St. Trudpert Klinikum, Pforzheim, Germany; Klinikum für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock, Rostock, Germany; Brustzentrum, DRK Kliniken, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Freiburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Ulm, Germany
| | - C Bechtner
- German Breast Group, Neu-Isenburg, Germany; Brustzentrum, Elisabeth Krankenhaus, Kassel, Germany; Brustzentrum, Kliniken Essen-Mitte, Essen, Germany; HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Universitätsmedizin Mainz, Mainz, Germany; Brustzentrum, Klinikum Memmingen, Memmingen, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Siloah St. Trudpert Klinikum, Pforzheim, Germany; Klinikum für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock, Rostock, Germany; Brustzentrum, DRK Kliniken, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Freiburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Ulm, Germany
| | - F Marmé
- German Breast Group, Neu-Isenburg, Germany; Brustzentrum, Elisabeth Krankenhaus, Kassel, Germany; Brustzentrum, Kliniken Essen-Mitte, Essen, Germany; HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Universitätsmedizin Mainz, Mainz, Germany; Brustzentrum, Klinikum Memmingen, Memmingen, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Siloah St. Trudpert Klinikum, Pforzheim, Germany; Klinikum für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock, Rostock, Germany; Brustzentrum, DRK Kliniken, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Freiburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Ulm, Germany
| | - M Wagner
- German Breast Group, Neu-Isenburg, Germany; Brustzentrum, Elisabeth Krankenhaus, Kassel, Germany; Brustzentrum, Kliniken Essen-Mitte, Essen, Germany; HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Universitätsmedizin Mainz, Mainz, Germany; Brustzentrum, Klinikum Memmingen, Memmingen, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Siloah St. Trudpert Klinikum, Pforzheim, Germany; Klinikum für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock, Rostock, Germany; Brustzentrum, DRK Kliniken, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Freiburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Ulm, Germany
| | - V Möbus
- German Breast Group, Neu-Isenburg, Germany; Brustzentrum, Elisabeth Krankenhaus, Kassel, Germany; Brustzentrum, Kliniken Essen-Mitte, Essen, Germany; HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Universitätsmedizin Mainz, Mainz, Germany; Brustzentrum, Klinikum Memmingen, Memmingen, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Siloah St. Trudpert Klinikum, Pforzheim, Germany; Klinikum für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock, Rostock, Germany; Brustzentrum, DRK Kliniken, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Freiburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Ulm, Germany
| | - T Reimer
- German Breast Group, Neu-Isenburg, Germany; Brustzentrum, Elisabeth Krankenhaus, Kassel, Germany; Brustzentrum, Kliniken Essen-Mitte, Essen, Germany; HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Universitätsmedizin Mainz, Mainz, Germany; Brustzentrum, Klinikum Memmingen, Memmingen, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Siloah St. Trudpert Klinikum, Pforzheim, Germany; Klinikum für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock, Rostock, Germany; Brustzentrum, DRK Kliniken, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Freiburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Ulm, Germany
| | - A Kleine-Tebbe
- German Breast Group, Neu-Isenburg, Germany; Brustzentrum, Elisabeth Krankenhaus, Kassel, Germany; Brustzentrum, Kliniken Essen-Mitte, Essen, Germany; HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Universitätsmedizin Mainz, Mainz, Germany; Brustzentrum, Klinikum Memmingen, Memmingen, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Siloah St. Trudpert Klinikum, Pforzheim, Germany; Klinikum für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock, Rostock, Germany; Brustzentrum, DRK Kliniken, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Freiburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Ulm, Germany
| | - B Sinn
- German Breast Group, Neu-Isenburg, Germany; Brustzentrum, Elisabeth Krankenhaus, Kassel, Germany; Brustzentrum, Kliniken Essen-Mitte, Essen, Germany; HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Universitätsmedizin Mainz, Mainz, Germany; Brustzentrum, Klinikum Memmingen, Memmingen, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Siloah St. Trudpert Klinikum, Pforzheim, Germany; Klinikum für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock, Rostock, Germany; Brustzentrum, DRK Kliniken, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Freiburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Ulm, Germany
| | - E Stickeler
- German Breast Group, Neu-Isenburg, Germany; Brustzentrum, Elisabeth Krankenhaus, Kassel, Germany; Brustzentrum, Kliniken Essen-Mitte, Essen, Germany; HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Universitätsmedizin Mainz, Mainz, Germany; Brustzentrum, Klinikum Memmingen, Memmingen, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Siloah St. Trudpert Klinikum, Pforzheim, Germany; Klinikum für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock, Rostock, Germany; Brustzentrum, DRK Kliniken, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Freiburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Ulm, Germany
| | - M Untch
- German Breast Group, Neu-Isenburg, Germany; Brustzentrum, Elisabeth Krankenhaus, Kassel, Germany; Brustzentrum, Kliniken Essen-Mitte, Essen, Germany; HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Universitätsmedizin Mainz, Mainz, Germany; Brustzentrum, Klinikum Memmingen, Memmingen, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Siloah St. Trudpert Klinikum, Pforzheim, Germany; Klinikum für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock, Rostock, Germany; Brustzentrum, DRK Kliniken, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Freiburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Ulm, Germany
| | - W Janni
- German Breast Group, Neu-Isenburg, Germany; Brustzentrum, Elisabeth Krankenhaus, Kassel, Germany; Brustzentrum, Kliniken Essen-Mitte, Essen, Germany; HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Universitätsmedizin Mainz, Mainz, Germany; Brustzentrum, Klinikum Memmingen, Memmingen, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Siloah St. Trudpert Klinikum, Pforzheim, Germany; Klinikum für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock, Rostock, Germany; Brustzentrum, DRK Kliniken, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Freiburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Ulm, Germany
| | - F Seither
- German Breast Group, Neu-Isenburg, Germany; Brustzentrum, Elisabeth Krankenhaus, Kassel, Germany; Brustzentrum, Kliniken Essen-Mitte, Essen, Germany; HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Universitätsmedizin Mainz, Mainz, Germany; Brustzentrum, Klinikum Memmingen, Memmingen, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Siloah St. Trudpert Klinikum, Pforzheim, Germany; Klinikum für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock, Rostock, Germany; Brustzentrum, DRK Kliniken, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Freiburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Ulm, Germany
| | - S Loibl
- German Breast Group, Neu-Isenburg, Germany; Brustzentrum, Elisabeth Krankenhaus, Kassel, Germany; Brustzentrum, Kliniken Essen-Mitte, Essen, Germany; HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Universitätsmedizin Mainz, Mainz, Germany; Brustzentrum, Klinikum Memmingen, Memmingen, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Siloah St. Trudpert Klinikum, Pforzheim, Germany; Klinikum für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock, Rostock, Germany; Brustzentrum, DRK Kliniken, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Freiburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Ulm, Germany
| |
Collapse
|
10
|
Sinn BV, Loibl S, Karn T, Untch M, Kunze CA, Weber KE, Treue D, Wagner K, Hanusch CA, Klauschen F, Fasching PA, Huober J, Zahm DM, Jackisch C, Thomalla J, Blohmer JU, van Mackelenbergh M, Rhiem K, Felder B, von Minckwitz G, Burchardi N, Schneeweiss A, Denkert C. Abstract PD5-05: Pre-therapeutic PD-L1 expression and dynamics of Ki-67 and gene expression during neoadjuvant immune-checkpoint blockade and chemotherapy to predict response within the GeparNuevo trial. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd5-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
In the GeparNuevo trial, the PD-L1 inhibitor durvalumab increased the rate of pathologic complete response (pCR; ypT0 ypN0) in triple-negative breast cancer if treatment started in a two-week window before neoadjuvant taxane/anthracycline chemotherapy (61 % pCR vs. 41%; p = 0.048; Loibl et al. ASCO 2018). Overall, pCR rates increased only numerically from 53 % to 44 % (p = 0.281). Herein, we aimed to evaluate the predictive value of PD-L1 immunohistochemistry in pre-therapeutic core biopsies. In addition, we identified dynamics in gene expression using repeated biopsies.
Patients and Methods
174 patients were randomized to receive durvalumab or placebo with neoadjuvant chemotherapy. In the window part, 117 patients received a single dose of durvalumab (or placebo) before chemotherapy. Core biopsies were taken at three times: pre-treatment (“A”; N=174), after the window part (“B”; N=88) and after 12 weeks of nab-Paclitaxel (“C”; N=33). PD-L1 immunohistochemistry in A-biopsies (Ventana SP263 Assay) was recorded as percentage of cells with membranous staining in tumor cells and lymphocytes (TILs). We defined a tumor as PD-L1 high if ≥ 25 % of either compartment was stained. Ki-67 was stained on all available A, B and C biopsies (MIB-1, Dako, 1:100) and recorded as the percentage of tumor cells with nuclear staining. We profiled all available biopsies with targeted RNASeq using the HTG EdgeSeq platform (Oncology Biomarker panel, 2560 genes). Sequencing (IonTorrent S5) was successful in 162 A-, 79 B- and 31 C-biopsies.
Results
PD-L1 expression was high in 24 % of A-biopsies and was predictive for pCR in the complete cohort (OR 2.561; 1.183-5.554; p = 0.017). PD-L1 status of the TILs, but not of the tumor cells, was predictive (OR 1.313; 1.040-1.656; P= 0.022). The effect was not specific for durvalumab treatment. Higher levels of Ki-67 were predictive for pCR in B- biopsies in all patients (OR 1.399; 1.053-1.858; P =0.021) and in the placebo arm, but not in the durvalumab arm. Ki-67 levels in C-biopsies were not predictive; neither was the change in Ki-67 between pre-treatment and later time points (B vs. A or C vs. A).
In a differential mRNA expression analysis (A vs. B), we found seven differentially expressed genes after one dose of durvalumab. We observed strong effects on gene expression after taxane treatment (A vs. C), but no significant difference according to treatment. These genes were associated with biological processes involved in therapy response. The pre-treatment levels of 12 of 69 markedly differentially expressed genes were associated with worse response to chemotherapy.
Conclusion
In A-biopsies, PD-L1 in TILs was predictive for response, and in B-biopsies, Ki-67 was predictive, but neither marker could specifically predict response to durvalumab. We observed limited effects of a single half-dose of durvalumab on global gene expression, but could identify substantial differential expression after taxane treatment. The evaluation of gene expression dynamic offers a promising approach for the identification of resistance-associated markers.
The study was financially supported by AstraZeneca and Celgene
Citation Format: Sinn BV, Loibl S, Karn T, Untch M, Kunze CA, Weber KE, Treue D, Wagner K, Hanusch CA, Klauschen F, Fasching PA, Huober J, Zahm D-M, Jackisch C, Thomalla J, Blohmer J-U, van Mackelenbergh M, Rhiem K, Felder B, von Minckwitz G, Burchardi N, Schneeweiss A, Denkert C. Pre-therapeutic PD-L1 expression and dynamics of Ki-67 and gene expression during neoadjuvant immune-checkpoint blockade and chemotherapy to predict response within the GeparNuevo trial [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD5-05.
Collapse
Affiliation(s)
- BV Sinn
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - S Loibl
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - T Karn
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - M Untch
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - CA Kunze
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - KE Weber
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - D Treue
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - K Wagner
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - CA Hanusch
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - F Klauschen
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - PA Fasching
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - J Huober
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - D-M Zahm
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - C Jackisch
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - J Thomalla
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - J-U Blohmer
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - M van Mackelenbergh
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - K Rhiem
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - B Felder
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - G von Minckwitz
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - N Burchardi
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - A Schneeweiss
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - C Denkert
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| |
Collapse
|
11
|
Villegas SL, Lederer B, Untch M, Holms F, Ulmer HU, Diebold K, Fasching PA, Weber K, Schmitt WD, Tesch H, Rezai M, Marmé F, Sinn B, Hackmann J, Schneeweiss A, Tannapfel A, Nekljudova V, Denkert C, Loibl S. Abstract P2-08-10: Similarities between low hormone receptor positive and hormone receptor negative breast cancer: An analysis of 4366 patients from multicenter clinical trials. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-08-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Currently, patients with breast cancer (BC) with hormone receptor (HR) immunohistochemical expression between 1-9% are eligible to receive endocrine therapy. However, recent data suggest that these tumors express a basal-like molecular phenotype associated with triple negative BC (TNBC) rather than luminal phenotype associated with HR positive BC. Here, we aimed to determine the differences between strong HR positive, low HR positive and negative HR BC, in regard to responsiveness to neoadjuvant chemotherapy (NACT) and disease free survival (DFS) in large cohorts from GBG clinical trials.
Methods:
In this retrospective analysis of data from women with BC treated in the neoadjuvant GeparQuinto (n=2572), GeparSixto (n=588) and GeparSepto (n=1206) clinical trials, we compared patients with three HR phenotypes: low positive (ER and/or PR= 1-9%), strong positive (ER or PR= 10-100%), and negative (ER and PR= <1%), regarding pathological complete response (pCR, ypT0 ypN0) and DFS. A logistic regression model for endpoint pCR was performed on pooled data from all trials. Cox regression was used to model DFS for patients participating in GeparQuinto and GeparSixto trial, including 71 with low HR positive phenotype. The models were adjusted by age, tumor and nodal status, grading, Her2 status, histological type, stromal and tumor infiltrating lymphocytes and clinical trial. The survival model was additionally adjusted by pCR after NACT.
Results:
Patients median age was 49 years, the majority had clinical tumor stage 2 (54.1%), negative nodal status (54.7%), and Her2 negative tumors (72.4%). 85.1% of women had BC classified as no special histological type. The pCR rate across the studies was 26.2%. 145 (3.4%) patients had low HR positive, 2417 (57.3%) strong HR positive and 1658 (39.3%) HR negative tumors. After NACT, 16.3% of patients with strong HR positive BC achieved a pCR, while among those with HR negative and low HR positive tumors, pCR rates were 40.2% and 37.9%, respectively (p<0.001). In the adjusted logistic regression model, there was no statistically significant difference between low HR positive and HR negative tumors (OR: 1.34, 95%-CI: (0.84-2.13), p=0.222). But strong HR positive tumors had a significantly lower chance of achieving a pCR compared to low HR positives (OR 0.48, 95%-CI: 0.30-0.76, p=0.002). Patients with strong HR positive BC had a better DFS than patients with low HR positive tumors (hazard ratio 0.35, 95%-CI: 0.18-0.70, p=0.003). DFS was not significantly different between patients with HR negative and low HR positive tumors (hazard ratio 0.74, 95%-CI: 0.38-1.43, p=0.370).
Conclusions:
Similarly to patients with negative HR tumors, patients with low HR positive tumors have a better responsiveness to NACT and worse survival rates, compared to patients with strongly HR positive BC. We suggest that studies on treatment options for basal-like/TNBC, should also consider including patients with low HR positive tumors.
Citation Format: Villegas SL, Lederer B, Untch M, Holms F, Ulmer H-U, Diebold K, Fasching PA, Weber K, Schmitt WD, Tesch H, Rezai M, Marmé F, Sinn B, Hackmann J, Schneeweiss A, Tannapfel A, Nekljudova V, Denkert C, Loibl S. Similarities between low hormone receptor positive and hormone receptor negative breast cancer: An analysis of 4366 patients from multicenter clinical trials [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-08-10.
Collapse
Affiliation(s)
- SL Villegas
- Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany; German Breast Group (GBG Forschungs GmbH), Neu-Isenburg, Germany; HELIOS Klinikum, Berlin, Germany; Institute of Pathology, St. Barbara Klinik, Hamm-Heessen, Germany; Mittelbaden Hospital, Karlsruhe, Germany; University Hospital Erlangen, Friedrich-Alexander University, Erlangen, Germany; Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; Luisenkrankenhaus, Medical Center Düsseldorf, Düsseldorf, Germany; National Center for Tumour Diseases and University Hospital Heidelberg, Heidelberg, Germany; Marien Hospital, Witten, Germany; Institute for Pathology, Ruhr-University, Bochum, Germany
| | - B Lederer
- Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany; German Breast Group (GBG Forschungs GmbH), Neu-Isenburg, Germany; HELIOS Klinikum, Berlin, Germany; Institute of Pathology, St. Barbara Klinik, Hamm-Heessen, Germany; Mittelbaden Hospital, Karlsruhe, Germany; University Hospital Erlangen, Friedrich-Alexander University, Erlangen, Germany; Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; Luisenkrankenhaus, Medical Center Düsseldorf, Düsseldorf, Germany; National Center for Tumour Diseases and University Hospital Heidelberg, Heidelberg, Germany; Marien Hospital, Witten, Germany; Institute for Pathology, Ruhr-University, Bochum, Germany
| | - M Untch
- Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany; German Breast Group (GBG Forschungs GmbH), Neu-Isenburg, Germany; HELIOS Klinikum, Berlin, Germany; Institute of Pathology, St. Barbara Klinik, Hamm-Heessen, Germany; Mittelbaden Hospital, Karlsruhe, Germany; University Hospital Erlangen, Friedrich-Alexander University, Erlangen, Germany; Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; Luisenkrankenhaus, Medical Center Düsseldorf, Düsseldorf, Germany; National Center for Tumour Diseases and University Hospital Heidelberg, Heidelberg, Germany; Marien Hospital, Witten, Germany; Institute for Pathology, Ruhr-University, Bochum, Germany
| | - F Holms
- Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany; German Breast Group (GBG Forschungs GmbH), Neu-Isenburg, Germany; HELIOS Klinikum, Berlin, Germany; Institute of Pathology, St. Barbara Klinik, Hamm-Heessen, Germany; Mittelbaden Hospital, Karlsruhe, Germany; University Hospital Erlangen, Friedrich-Alexander University, Erlangen, Germany; Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; Luisenkrankenhaus, Medical Center Düsseldorf, Düsseldorf, Germany; National Center for Tumour Diseases and University Hospital Heidelberg, Heidelberg, Germany; Marien Hospital, Witten, Germany; Institute for Pathology, Ruhr-University, Bochum, Germany
| | - H-U Ulmer
- Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany; German Breast Group (GBG Forschungs GmbH), Neu-Isenburg, Germany; HELIOS Klinikum, Berlin, Germany; Institute of Pathology, St. Barbara Klinik, Hamm-Heessen, Germany; Mittelbaden Hospital, Karlsruhe, Germany; University Hospital Erlangen, Friedrich-Alexander University, Erlangen, Germany; Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; Luisenkrankenhaus, Medical Center Düsseldorf, Düsseldorf, Germany; National Center for Tumour Diseases and University Hospital Heidelberg, Heidelberg, Germany; Marien Hospital, Witten, Germany; Institute for Pathology, Ruhr-University, Bochum, Germany
| | - K Diebold
- Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany; German Breast Group (GBG Forschungs GmbH), Neu-Isenburg, Germany; HELIOS Klinikum, Berlin, Germany; Institute of Pathology, St. Barbara Klinik, Hamm-Heessen, Germany; Mittelbaden Hospital, Karlsruhe, Germany; University Hospital Erlangen, Friedrich-Alexander University, Erlangen, Germany; Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; Luisenkrankenhaus, Medical Center Düsseldorf, Düsseldorf, Germany; National Center for Tumour Diseases and University Hospital Heidelberg, Heidelberg, Germany; Marien Hospital, Witten, Germany; Institute for Pathology, Ruhr-University, Bochum, Germany
| | - PA Fasching
- Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany; German Breast Group (GBG Forschungs GmbH), Neu-Isenburg, Germany; HELIOS Klinikum, Berlin, Germany; Institute of Pathology, St. Barbara Klinik, Hamm-Heessen, Germany; Mittelbaden Hospital, Karlsruhe, Germany; University Hospital Erlangen, Friedrich-Alexander University, Erlangen, Germany; Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; Luisenkrankenhaus, Medical Center Düsseldorf, Düsseldorf, Germany; National Center for Tumour Diseases and University Hospital Heidelberg, Heidelberg, Germany; Marien Hospital, Witten, Germany; Institute for Pathology, Ruhr-University, Bochum, Germany
| | - K Weber
- Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany; German Breast Group (GBG Forschungs GmbH), Neu-Isenburg, Germany; HELIOS Klinikum, Berlin, Germany; Institute of Pathology, St. Barbara Klinik, Hamm-Heessen, Germany; Mittelbaden Hospital, Karlsruhe, Germany; University Hospital Erlangen, Friedrich-Alexander University, Erlangen, Germany; Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; Luisenkrankenhaus, Medical Center Düsseldorf, Düsseldorf, Germany; National Center for Tumour Diseases and University Hospital Heidelberg, Heidelberg, Germany; Marien Hospital, Witten, Germany; Institute for Pathology, Ruhr-University, Bochum, Germany
| | - WD Schmitt
- Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany; German Breast Group (GBG Forschungs GmbH), Neu-Isenburg, Germany; HELIOS Klinikum, Berlin, Germany; Institute of Pathology, St. Barbara Klinik, Hamm-Heessen, Germany; Mittelbaden Hospital, Karlsruhe, Germany; University Hospital Erlangen, Friedrich-Alexander University, Erlangen, Germany; Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; Luisenkrankenhaus, Medical Center Düsseldorf, Düsseldorf, Germany; National Center for Tumour Diseases and University Hospital Heidelberg, Heidelberg, Germany; Marien Hospital, Witten, Germany; Institute for Pathology, Ruhr-University, Bochum, Germany
| | - H Tesch
- Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany; German Breast Group (GBG Forschungs GmbH), Neu-Isenburg, Germany; HELIOS Klinikum, Berlin, Germany; Institute of Pathology, St. Barbara Klinik, Hamm-Heessen, Germany; Mittelbaden Hospital, Karlsruhe, Germany; University Hospital Erlangen, Friedrich-Alexander University, Erlangen, Germany; Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; Luisenkrankenhaus, Medical Center Düsseldorf, Düsseldorf, Germany; National Center for Tumour Diseases and University Hospital Heidelberg, Heidelberg, Germany; Marien Hospital, Witten, Germany; Institute for Pathology, Ruhr-University, Bochum, Germany
| | - M Rezai
- Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany; German Breast Group (GBG Forschungs GmbH), Neu-Isenburg, Germany; HELIOS Klinikum, Berlin, Germany; Institute of Pathology, St. Barbara Klinik, Hamm-Heessen, Germany; Mittelbaden Hospital, Karlsruhe, Germany; University Hospital Erlangen, Friedrich-Alexander University, Erlangen, Germany; Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; Luisenkrankenhaus, Medical Center Düsseldorf, Düsseldorf, Germany; National Center for Tumour Diseases and University Hospital Heidelberg, Heidelberg, Germany; Marien Hospital, Witten, Germany; Institute for Pathology, Ruhr-University, Bochum, Germany
| | - F Marmé
- Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany; German Breast Group (GBG Forschungs GmbH), Neu-Isenburg, Germany; HELIOS Klinikum, Berlin, Germany; Institute of Pathology, St. Barbara Klinik, Hamm-Heessen, Germany; Mittelbaden Hospital, Karlsruhe, Germany; University Hospital Erlangen, Friedrich-Alexander University, Erlangen, Germany; Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; Luisenkrankenhaus, Medical Center Düsseldorf, Düsseldorf, Germany; National Center for Tumour Diseases and University Hospital Heidelberg, Heidelberg, Germany; Marien Hospital, Witten, Germany; Institute for Pathology, Ruhr-University, Bochum, Germany
| | - B Sinn
- Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany; German Breast Group (GBG Forschungs GmbH), Neu-Isenburg, Germany; HELIOS Klinikum, Berlin, Germany; Institute of Pathology, St. Barbara Klinik, Hamm-Heessen, Germany; Mittelbaden Hospital, Karlsruhe, Germany; University Hospital Erlangen, Friedrich-Alexander University, Erlangen, Germany; Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; Luisenkrankenhaus, Medical Center Düsseldorf, Düsseldorf, Germany; National Center for Tumour Diseases and University Hospital Heidelberg, Heidelberg, Germany; Marien Hospital, Witten, Germany; Institute for Pathology, Ruhr-University, Bochum, Germany
| | - J Hackmann
- Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany; German Breast Group (GBG Forschungs GmbH), Neu-Isenburg, Germany; HELIOS Klinikum, Berlin, Germany; Institute of Pathology, St. Barbara Klinik, Hamm-Heessen, Germany; Mittelbaden Hospital, Karlsruhe, Germany; University Hospital Erlangen, Friedrich-Alexander University, Erlangen, Germany; Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; Luisenkrankenhaus, Medical Center Düsseldorf, Düsseldorf, Germany; National Center for Tumour Diseases and University Hospital Heidelberg, Heidelberg, Germany; Marien Hospital, Witten, Germany; Institute for Pathology, Ruhr-University, Bochum, Germany
| | - A Schneeweiss
- Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany; German Breast Group (GBG Forschungs GmbH), Neu-Isenburg, Germany; HELIOS Klinikum, Berlin, Germany; Institute of Pathology, St. Barbara Klinik, Hamm-Heessen, Germany; Mittelbaden Hospital, Karlsruhe, Germany; University Hospital Erlangen, Friedrich-Alexander University, Erlangen, Germany; Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; Luisenkrankenhaus, Medical Center Düsseldorf, Düsseldorf, Germany; National Center for Tumour Diseases and University Hospital Heidelberg, Heidelberg, Germany; Marien Hospital, Witten, Germany; Institute for Pathology, Ruhr-University, Bochum, Germany
| | - A Tannapfel
- Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany; German Breast Group (GBG Forschungs GmbH), Neu-Isenburg, Germany; HELIOS Klinikum, Berlin, Germany; Institute of Pathology, St. Barbara Klinik, Hamm-Heessen, Germany; Mittelbaden Hospital, Karlsruhe, Germany; University Hospital Erlangen, Friedrich-Alexander University, Erlangen, Germany; Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; Luisenkrankenhaus, Medical Center Düsseldorf, Düsseldorf, Germany; National Center for Tumour Diseases and University Hospital Heidelberg, Heidelberg, Germany; Marien Hospital, Witten, Germany; Institute for Pathology, Ruhr-University, Bochum, Germany
| | - V Nekljudova
- Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany; German Breast Group (GBG Forschungs GmbH), Neu-Isenburg, Germany; HELIOS Klinikum, Berlin, Germany; Institute of Pathology, St. Barbara Klinik, Hamm-Heessen, Germany; Mittelbaden Hospital, Karlsruhe, Germany; University Hospital Erlangen, Friedrich-Alexander University, Erlangen, Germany; Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; Luisenkrankenhaus, Medical Center Düsseldorf, Düsseldorf, Germany; National Center for Tumour Diseases and University Hospital Heidelberg, Heidelberg, Germany; Marien Hospital, Witten, Germany; Institute for Pathology, Ruhr-University, Bochum, Germany
| | - C Denkert
- Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany; German Breast Group (GBG Forschungs GmbH), Neu-Isenburg, Germany; HELIOS Klinikum, Berlin, Germany; Institute of Pathology, St. Barbara Klinik, Hamm-Heessen, Germany; Mittelbaden Hospital, Karlsruhe, Germany; University Hospital Erlangen, Friedrich-Alexander University, Erlangen, Germany; Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; Luisenkrankenhaus, Medical Center Düsseldorf, Düsseldorf, Germany; National Center for Tumour Diseases and University Hospital Heidelberg, Heidelberg, Germany; Marien Hospital, Witten, Germany; Institute for Pathology, Ruhr-University, Bochum, Germany
| | - S Loibl
- Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany; German Breast Group (GBG Forschungs GmbH), Neu-Isenburg, Germany; HELIOS Klinikum, Berlin, Germany; Institute of Pathology, St. Barbara Klinik, Hamm-Heessen, Germany; Mittelbaden Hospital, Karlsruhe, Germany; University Hospital Erlangen, Friedrich-Alexander University, Erlangen, Germany; Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; Luisenkrankenhaus, Medical Center Düsseldorf, Düsseldorf, Germany; National Center for Tumour Diseases and University Hospital Heidelberg, Heidelberg, Germany; Marien Hospital, Witten, Germany; Institute for Pathology, Ruhr-University, Bochum, Germany
| |
Collapse
|
12
|
Marczyk M, Fu C, Lau R, Du L, Trevarton AJ, Sinn BV, Gould RE, Symmans WF, Hatzis C. Abstract P4-08-20: Pre-analytical effects of FFPE extraction methods on targeted and whole transcriptome sequencing assays for endocrine sensitivity in metastatic breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-08-20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The clinical management of patients with metastatic HR-positive breast cancer is often uncertain due to decreased sensitivity to anti-estrogen therapy over time. Recently, we developed a targeted RNAseq based 18-transcript SET ER/PR assay of endocrine sensitivity from biopsies of metastatic cancer. In this work we assess the effect of pre-analytical factors, specifically RNA extraction methods for FFPE tissue samples, on the reliability of the targeted RNAseq assay.
Methods: FFPE blocks and matched fresh frozen (FF) sections from 12 tumors were collected at MD Anderson Cancer Center. RNA from FFPE slides was extracted in duplicate using three kits (Norgen, Qiagen, Roche), and RNAseq libraries from all samples were prepared using Kapa Total RNAseq kit. Targeted RNA libraries were prepared using droplet-based PCR (RainDance), and also by transcriptome-wide RNAseq for comparison. Reads were mapped to genomic sequence using STAR and expression was quantified using RSEM. Expression data were normalized based on expression of 10 reference genes. The effect of FFPE RNA extraction kit on the reliability of the SET index was assessed using linear mixed effects model (LME) analysis, and agreement with FF was assessed using the concordance correlation coefficient (CCC).
Results: Analysis of the whole transcriptome RNAseq data confirmed minimal 3'-end transcript bias from FFPE samples, irrespective of transcript size or FFPE kit. All 18 genes included in the SET index had high overall concordance between FFPE and FF (median CCC percentile=98.8, range 57.2-99.9 for Norgen; similar for the other two kits) and relatively consistent bias across genes, as estimated by the random effects of the LME model. Furthermore, compared to random 18-gene indices, concordance in the SET index values between FF and FFPE was higher than 99.8% of the random samples, verifying the analytical reliability of the selected genes. For the targeted RNAseq assay, RNA from FFPE extracted with the Norgen kit showed the highest concordance compared to FF (CCC=0.956, 95%CI 0.871-0.985). In general, the analytical variation of SET from FFPE samples was greater than that from FF (1.71-2.71 fold greater), with the lowest variation associated with the Norgen kit. The SET index values from targeted RNAseq for both FF and FFPE samples were consistently lower compared to transcriptome-wide RNAseq but were highly correlated, with the Norgen kit having the highest correlation between targeted and transcriptome-wide RNAseq (rho=0.915).
Conclusions: All three FFPE RNA extraction kits have excellent analytical performance compared to FF samples. The Norgen kit may be marginally better yielding higher concordance with FF and lower analytical variation between replicates. All genes in the SET ER/PR showed very good analytical performance in comparison to random indices and individual genes. Targeted gene RNA sequencing appears very promising as a platform for clinical deployment of quantitative assays, showing only a small (fixable) bias compared to RNAseq.
Citation Format: Marczyk M, Fu C, Lau R, Du L, Trevarton AJ, Sinn BV, Gould RE, Symmans WF, Hatzis C. Pre-analytical effects of FFPE extraction methods on targeted and whole transcriptome sequencing assays for endocrine sensitivity in metastatic breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-08-20.
Collapse
Affiliation(s)
- M Marczyk
- Yale School of Medicine, New Haven, CT; The University of Texas MD Anderson Cancer Center, Houston, TX; Charité Universitätsmedizin Berlin, Berlin, Germany; Silesian University of Technology, Gliwice, Poland
| | - C Fu
- Yale School of Medicine, New Haven, CT; The University of Texas MD Anderson Cancer Center, Houston, TX; Charité Universitätsmedizin Berlin, Berlin, Germany; Silesian University of Technology, Gliwice, Poland
| | - R Lau
- Yale School of Medicine, New Haven, CT; The University of Texas MD Anderson Cancer Center, Houston, TX; Charité Universitätsmedizin Berlin, Berlin, Germany; Silesian University of Technology, Gliwice, Poland
| | - L Du
- Yale School of Medicine, New Haven, CT; The University of Texas MD Anderson Cancer Center, Houston, TX; Charité Universitätsmedizin Berlin, Berlin, Germany; Silesian University of Technology, Gliwice, Poland
| | - AJ Trevarton
- Yale School of Medicine, New Haven, CT; The University of Texas MD Anderson Cancer Center, Houston, TX; Charité Universitätsmedizin Berlin, Berlin, Germany; Silesian University of Technology, Gliwice, Poland
| | - BV Sinn
- Yale School of Medicine, New Haven, CT; The University of Texas MD Anderson Cancer Center, Houston, TX; Charité Universitätsmedizin Berlin, Berlin, Germany; Silesian University of Technology, Gliwice, Poland
| | - RE Gould
- Yale School of Medicine, New Haven, CT; The University of Texas MD Anderson Cancer Center, Houston, TX; Charité Universitätsmedizin Berlin, Berlin, Germany; Silesian University of Technology, Gliwice, Poland
| | - WF Symmans
- Yale School of Medicine, New Haven, CT; The University of Texas MD Anderson Cancer Center, Houston, TX; Charité Universitätsmedizin Berlin, Berlin, Germany; Silesian University of Technology, Gliwice, Poland
| | - C Hatzis
- Yale School of Medicine, New Haven, CT; The University of Texas MD Anderson Cancer Center, Houston, TX; Charité Universitätsmedizin Berlin, Berlin, Germany; Silesian University of Technology, Gliwice, Poland
| |
Collapse
|
13
|
Loibl S, Sinn BV, Karn T, Untch M, Treue D, Sinn HP, Weber KE, Hanusch CA, Fasching PA, Huober J, Zahm DM, Jackisch C, Thomalla J, Blohmer JU, Marmé F, Klauschen F, Rhiem K, Felder B, von Minckwitz G, Burchardi N, Schneeweiss A, Denkert C. Abstract PD2-07: mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC)– Results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd2-07] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The GeparNuevo trial showed a numerical increase in the pCR rate to 53% vs 44%; p=0.281 compared to placebo in TNBC with the addition of the anti-PD-L1 antibody durvalumab to a neoadjuvant anthracycline-taxane containing chemotherapy (Loibl S et al. ASCO 2018). In a predefined subgroup analysis, a significant increase of the pCR rate was observed for patients that received durvalumab for 2 weeks alone prior to the start of chemotherapy in a window phase (61% vs 41%, p interaction=0.048), while the pCR rate was not increased for the subset of patients that did start durvalumab together with chemotherapy.
Here we report the main results of the translational programme for GeparNuevo with a focus on mRNA signatures predictive for pCR in pretherapeutic core biopsies.
Methods: A total of 162 baseline FFPE core biopsies were evaluable for expression of 2560 genes using the HTG EdgeSeq® system that combines a modified nuclease protection assay with next generation sequencing. Data was processed as recommended by the HTG and median transformed for further analyses. For differential gene expression analyses, the data was scale-normalized (TMM normalization; EdgeR package) and linear models were fit (limma package). Prior to these analyses, genes were filtered based on minimal expression (> 4) and variability (IQR > 1). As a first step, predefined immune-genes signature (TILs signature) (Denkert et al. JCO 2016) as well as IFN-gamma signatures were evaluated for correlation with pCR in logistic regression models. Subsequently, we performed a differential gene expression analysis according to therapy response for the durvalumab-arm and the placebo arm using the pre-filtered candidate genes. Gene names are not included in this abstract to allow filing of IP, but full gene names will be presented at the SABCS meeting.
Results: The predefined TIL- and IFN-gamma signatures were associated with increased pCR rates in the complete cohort (TIL-signature: OR 1.44, 95% CI 1.15-1.82, p=0.002; IFN-Gamma-signature: OR 1.63, 95% CI 1.22-2.24, p=0.002) as well as in the durvalumab arm (p=0.012 and 0.042) and the placebo arm (p=0.050 and 0.011). These signatures were general pCR predictors without specificity for durvalumab response.
Additional 44 genes were significantly (p<0.05) correlated with pCR in the durvalumab arm. Of those, 21 genes were upregulated and 23 genes were downregulated in pCR patients. 14 of the 21 upregulated genes are related to tumorbiologically relevant immune cell functions. A total of 6 of the 44 genes had a positive test for interaction (interaction p<0.05) with the therapy arm (durvalumab + NACT vs. placebo + NACT), suggesting that these genes might specifically predict response to durvalumab. Additional analyses investigating the role of molecular tumor subtypes, additional immune gene signatures and other subgroup analyses will be presented at the meeting.
Conclusion: Our results show that specific immune-related gene expression signatures predict response to durvalumab in primary triple negative breast cancer.
The trial was financially supported by Astra Zeneca and Celgene
Citation Format: Loibl S, Sinn BV, Karn T, Untch M, Treue D, Sinn H-P, Weber KE, Hanusch CA, Fasching PA, Huober J, Zahm D-M, Jackisch C, Thomalla J, Blohmer J-U, Marmé F, Klauschen F, Rhiem K, Felder B, von Minckwitz G, Burchardi N, Schneeweiss A, Denkert C. mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC)– Results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD2-07.
Collapse
Affiliation(s)
- S Loibl
- German Breast Group, Neu-Isenburg, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Allgemeine Pathologie, Universitätsklinikum, Heidelberg, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany
| | - BV Sinn
- German Breast Group, Neu-Isenburg, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Allgemeine Pathologie, Universitätsklinikum, Heidelberg, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany
| | - T Karn
- German Breast Group, Neu-Isenburg, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Allgemeine Pathologie, Universitätsklinikum, Heidelberg, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany
| | - M Untch
- German Breast Group, Neu-Isenburg, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Allgemeine Pathologie, Universitätsklinikum, Heidelberg, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany
| | - D Treue
- German Breast Group, Neu-Isenburg, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Allgemeine Pathologie, Universitätsklinikum, Heidelberg, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany
| | - H-P Sinn
- German Breast Group, Neu-Isenburg, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Allgemeine Pathologie, Universitätsklinikum, Heidelberg, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany
| | - KE Weber
- German Breast Group, Neu-Isenburg, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Allgemeine Pathologie, Universitätsklinikum, Heidelberg, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany
| | - CA Hanusch
- German Breast Group, Neu-Isenburg, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Allgemeine Pathologie, Universitätsklinikum, Heidelberg, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany
| | - PA Fasching
- German Breast Group, Neu-Isenburg, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Allgemeine Pathologie, Universitätsklinikum, Heidelberg, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany
| | - J Huober
- German Breast Group, Neu-Isenburg, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Allgemeine Pathologie, Universitätsklinikum, Heidelberg, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany
| | - D-M Zahm
- German Breast Group, Neu-Isenburg, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Allgemeine Pathologie, Universitätsklinikum, Heidelberg, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany
| | - C Jackisch
- German Breast Group, Neu-Isenburg, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Allgemeine Pathologie, Universitätsklinikum, Heidelberg, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany
| | - J Thomalla
- German Breast Group, Neu-Isenburg, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Allgemeine Pathologie, Universitätsklinikum, Heidelberg, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany
| | - J-U Blohmer
- German Breast Group, Neu-Isenburg, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Allgemeine Pathologie, Universitätsklinikum, Heidelberg, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany
| | - F Marmé
- German Breast Group, Neu-Isenburg, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Allgemeine Pathologie, Universitätsklinikum, Heidelberg, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany
| | - F Klauschen
- German Breast Group, Neu-Isenburg, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Allgemeine Pathologie, Universitätsklinikum, Heidelberg, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany
| | - K Rhiem
- German Breast Group, Neu-Isenburg, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Allgemeine Pathologie, Universitätsklinikum, Heidelberg, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany
| | - B Felder
- German Breast Group, Neu-Isenburg, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Allgemeine Pathologie, Universitätsklinikum, Heidelberg, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany
| | - G von Minckwitz
- German Breast Group, Neu-Isenburg, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Allgemeine Pathologie, Universitätsklinikum, Heidelberg, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany
| | - N Burchardi
- German Breast Group, Neu-Isenburg, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Allgemeine Pathologie, Universitätsklinikum, Heidelberg, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany
| | - A Schneeweiss
- German Breast Group, Neu-Isenburg, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Allgemeine Pathologie, Universitätsklinikum, Heidelberg, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany
| | - C Denkert
- German Breast Group, Neu-Isenburg, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Allgemeine Pathologie, Universitätsklinikum, Heidelberg, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany
| |
Collapse
|
14
|
Reinisch M, Seiler S, Hauzenberger T, Schmatloch S, Strittmatter HJ, Zahm DM, Thode C, Jackisch C, Strik D, Moebus V, Reimer T, Sinn B, Stickeler E, Marme F, Janni W, Kamischke A, Rudlowski C, Nekljudova V, von Minckwitz G, Loibl S. Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Karn T, Meissner T, Weber K, Sinn B, Denkert C, Budczies J, Nekljudova V, Fasching PA, Holtrich U, Schem C, Solbach C, Hartmann A, Röcken C, Untch M, Young BM, Willis S, Leyland-Jones B, von Minckwitz G, Loibl S. Abstract P2-09-02: Blinded molecular subtyping analysis from RNA-Seq of FFPE samples in the GeparQuinto trial reveals predictive value of VEGFA metagene for bevacizumab treatment. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-09-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
RNA-Seq from total RNA in FFPE tissue can be more challenging due to limited capture of partially degraded RNA. Exome-capture based RNA-Seq may circumvent such problems and allow reproducible complete molecular characterization of low-quality RNA from small clinical samples.
Methods:
HER2 negative patients within the GeparQuinto trial were treated with neoadjuvant anthracycline-taxane-based chemotherapy +/- bevacizumab. Patients with bevacizumab therapy had a significantly higher pCR rate, especially within the triple negative subgroup. We performed exome-capture RNA-Seq on 5µm FFPE sections from pre-therapeutic cores of 400 HER2 negative samples from this trial. In a prospectively planned, blinded study we correlated molecular subtypes and metagenes for proliferation, stroma, MHC2, and VEGFA with clinical and histopathological data. Molecular subtypes were defined using the AIMS methods. Metagenes were calculated as mean values corresponding to previously described gene clusters after platform transfer (Rody et al. 2011 PMID 21978456, Hu et al. 2009 PMID 19291283) and then z-transformed.
Results:
296 samples with RNA-Seq data were classified as either of high (n=226) or of limited quality (n=70). For 22 samples RNA yield was insufficient and 82 did not pass initial QC. 121 (41%), 63 (21%), 34 (11.5%), 46 (15.5%), and 32 (11%) samples were defined as basal-like, HER2-enriched, luminal A, luminal B, and normal-like, respectively. Subtyping was robust with regard to gene filtering, normalization, and sample quality. ER and PR status from local IHC strongly correlated with gene expression (overall correctness 84% and 80% for ER, and 85% and 74% for PR, in samples with high and limited quality, respectively) and luminal subtypes (95% ER positive). Proliferation metagene correlated with histological grade (median -0.73, -0.39, and 0.53 in G1, G2, and G3, respectively; P<0.001) and MHC2 metagene correlated strongly with TIL counts (Rho=0.53, P<0.001). Among the high quality samples response rates (49.3% pCR overall) differed significantly by subtype, with higher pCR rates in basal-like (68.9%) and HER2-enriched (45.5%) than in luminal B (35.7%), luminal A (17.9%), and normal-like (20.0%). MHC2- (OR 1.60, 95%CI 1.21-2.12, P=0.001), proliferation- (OR 2.88, 95%CI 2.00-4.16, P<0.001), and VEGFA-metagenes (OR 1.92, 95%CI 1.41-2.60, P<0.001) were significant predictors for pCR. In a multivariate logistic regression (adjusted for bevacizumab treatment and hormone receptor status) both VEGFA metagene (OR 2.59, 95%CI 1.40-4.77, P=0.002) and the interaction between the VEGFA-metagene and bevacizumab treatment arm (P=0.023) significantly predicted pCR.
Conclusions:
Exome-capture RNA-Seq allows robust genomic characterization of clinical samples with limited FFPE material from core biopsies, and molecular subtypes and immune metagenes are predictive for pCR. The VEGFA metagene is a specific predictor for response to neoadjuvant bevacizumab treatment.
Citation Format: Karn T, Meissner T, Weber K, Sinn B, Denkert C, Budczies J, Nekljudova V, Fasching PA, Holtrich U, Schem C, Solbach C, Hartmann A, Röcken C, Untch M, Young BM, Willis S, Leyland-Jones B, von Minckwitz G, Loibl S. Blinded molecular subtyping analysis from RNA-Seq of FFPE samples in the GeparQuinto trial reveals predictive value of VEGFA metagene for bevacizumab treatment [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-09-02.
Collapse
Affiliation(s)
- T Karn
- Goethe University, Frankfurt; Avera Cancer Institute; German Breast Group; Charite University; University Hospital Erlangen; University Hospital Schleswig-Holstein Kiel; Helios Kliniken Berlin-Buch
| | - T Meissner
- Goethe University, Frankfurt; Avera Cancer Institute; German Breast Group; Charite University; University Hospital Erlangen; University Hospital Schleswig-Holstein Kiel; Helios Kliniken Berlin-Buch
| | - K Weber
- Goethe University, Frankfurt; Avera Cancer Institute; German Breast Group; Charite University; University Hospital Erlangen; University Hospital Schleswig-Holstein Kiel; Helios Kliniken Berlin-Buch
| | - B Sinn
- Goethe University, Frankfurt; Avera Cancer Institute; German Breast Group; Charite University; University Hospital Erlangen; University Hospital Schleswig-Holstein Kiel; Helios Kliniken Berlin-Buch
| | - C Denkert
- Goethe University, Frankfurt; Avera Cancer Institute; German Breast Group; Charite University; University Hospital Erlangen; University Hospital Schleswig-Holstein Kiel; Helios Kliniken Berlin-Buch
| | - J Budczies
- Goethe University, Frankfurt; Avera Cancer Institute; German Breast Group; Charite University; University Hospital Erlangen; University Hospital Schleswig-Holstein Kiel; Helios Kliniken Berlin-Buch
| | - V Nekljudova
- Goethe University, Frankfurt; Avera Cancer Institute; German Breast Group; Charite University; University Hospital Erlangen; University Hospital Schleswig-Holstein Kiel; Helios Kliniken Berlin-Buch
| | - PA Fasching
- Goethe University, Frankfurt; Avera Cancer Institute; German Breast Group; Charite University; University Hospital Erlangen; University Hospital Schleswig-Holstein Kiel; Helios Kliniken Berlin-Buch
| | - U Holtrich
- Goethe University, Frankfurt; Avera Cancer Institute; German Breast Group; Charite University; University Hospital Erlangen; University Hospital Schleswig-Holstein Kiel; Helios Kliniken Berlin-Buch
| | - C Schem
- Goethe University, Frankfurt; Avera Cancer Institute; German Breast Group; Charite University; University Hospital Erlangen; University Hospital Schleswig-Holstein Kiel; Helios Kliniken Berlin-Buch
| | - C Solbach
- Goethe University, Frankfurt; Avera Cancer Institute; German Breast Group; Charite University; University Hospital Erlangen; University Hospital Schleswig-Holstein Kiel; Helios Kliniken Berlin-Buch
| | - A Hartmann
- Goethe University, Frankfurt; Avera Cancer Institute; German Breast Group; Charite University; University Hospital Erlangen; University Hospital Schleswig-Holstein Kiel; Helios Kliniken Berlin-Buch
| | - C Röcken
- Goethe University, Frankfurt; Avera Cancer Institute; German Breast Group; Charite University; University Hospital Erlangen; University Hospital Schleswig-Holstein Kiel; Helios Kliniken Berlin-Buch
| | - M Untch
- Goethe University, Frankfurt; Avera Cancer Institute; German Breast Group; Charite University; University Hospital Erlangen; University Hospital Schleswig-Holstein Kiel; Helios Kliniken Berlin-Buch
| | - BM Young
- Goethe University, Frankfurt; Avera Cancer Institute; German Breast Group; Charite University; University Hospital Erlangen; University Hospital Schleswig-Holstein Kiel; Helios Kliniken Berlin-Buch
| | - S Willis
- Goethe University, Frankfurt; Avera Cancer Institute; German Breast Group; Charite University; University Hospital Erlangen; University Hospital Schleswig-Holstein Kiel; Helios Kliniken Berlin-Buch
| | - B Leyland-Jones
- Goethe University, Frankfurt; Avera Cancer Institute; German Breast Group; Charite University; University Hospital Erlangen; University Hospital Schleswig-Holstein Kiel; Helios Kliniken Berlin-Buch
| | - G von Minckwitz
- Goethe University, Frankfurt; Avera Cancer Institute; German Breast Group; Charite University; University Hospital Erlangen; University Hospital Schleswig-Holstein Kiel; Helios Kliniken Berlin-Buch
| | - S Loibl
- Goethe University, Frankfurt; Avera Cancer Institute; German Breast Group; Charite University; University Hospital Erlangen; University Hospital Schleswig-Holstein Kiel; Helios Kliniken Berlin-Buch
| |
Collapse
|
16
|
Möbus V, Mahlberg R, Janni W, Tomé O, Marmé F, Forstbauer H, Reimer T, von der Assen A, Reinisch M, Lorenz R, Schmatloch S, Schmidt M, Sinn B, Klutinus N, Stickeler E, Untch M, Seiler S, Burchardi N, von Minckwitz G, Loibl S. Abstract P5-20-09: Pharmacokinetic results of a subcutaneous injection of trastuzumab into the thigh versus into the abdominal wall in patients with HER2-positive primary breast cancer (BC) treated within the neo-/adjuvant GAIN-2 study. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-20-09] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
A new subcutaneous (s.c.) formulation of trastuzumab became available in 2013 based on equivalent efficacy, pharmacokinetic (PK) profile and safety with the standard intravenous (i.v.) administration, where the s.c. trastuzumab was administered only into the thigh. As an s.c. injection into the abdominal wall (abdw) might be more convenient for patients (pts) and health care professionals, the PK profile of s.c. trastuzumab injected into the thigh vs the abdw in pts with HER2+ early BC needs to be evaluated.
Methods
GAIN-2 study compared two intense dose-dense (idd) anthracycline/taxane containing regimens. After completion of the anthracycline and i.v. trastuzumab given concurrently with taxanes, HER2+ BC pts were randomized in a 1:1 ratio to continue adjuvant s.c. trastuzumab 600mg fixed dose injected every 3 weeks either into the thigh or the abdw. Randomization was stratified according to CT arm [(iddEnPC) vs tailored dd CT (dtEC-dtD)] and age (≤50 vs >50). Pts in the EnPC arm received 14 and in the dtEC-dtD arm 15 cycles of s.c. trastuzumab.
For the PK profile of s.c. trastuzumab serum samples collected before cycle 7, on days 2, 4, 8, 15 and 21 of cycle 7 are evaluated. With a total sample size of 30 (15 per group), the simulated 90% two-sided CI for the area under the plasma concentration (AUC0-last) will be (0.79-1.27) and for the peak drug concentration (Cmax) will be (0.77-1.30). Allowing for a dropout rate of 15%, 18 pts per group will be included in the PK analysis.
The primary objective was to assess the PK profile of s.c. trastuzumab injected into the thigh vs the abdw. The secondary objectives included safety and tolerability.
Results
The per-protocol (pp) set consists of 30 pts (17 in the thigh group and 13 in the abdw group). Baseline characteristics were well balanced between the groups. The log-transformed Geometric Least Square Means (GLSM) for Cmax were 11.77 and 11.52 in the thigh and the abdw group, respectively. The geo-mean ratio (on the original scale) for Cmax was 1.29 (90% CI 1.05-1.58). The log-transformed GLSM for AUC0-last were 14.54 and 14.28 in the thigh and the abdw group, respectively. The geo-mean ratio for AUC0-last was 1.29 (90% CI 1.02-1.63).
Overall 29 pts (96.7%) reported any grade and 5 pts (16.7%) high grade adverse events (AEs). The incidence of any grade AEs was similar between the two groups. The most common AEs were anemia (70.6% for the thigh vs 61.5% for the abdw group, p=0.705), leukopenia (80.0% for both groups, p=1.000) and fatigue (47.1% for the thigh vs 76.9% for the abdw group, p=0.141). 6 serious AEs were reported (2 in the thigh vs 4 in the abdw group). The final PK results of s.c. trastuzumab will be presented at the meeting.
Conclusions
Bioavailability of s.c. trastuzumab as reflected by peak and total exposure measured in cycle 7 was approx. 30% higher if administered into the thigh than into the abdw in pts with HER2+ primary BC treated after dose-dense CT plus i.v. trastuzumab. However, no increased toxicity was observed. Study limitations were that no cross-over design was used and number of pts satisfying criteria for pp-set were different in the arms.
Citation Format: Möbus V, Mahlberg R, Janni W, Tomé O, Marmé F, Forstbauer H, Reimer T, von der Assen A, Reinisch M, Lorenz R, Schmatloch S, Schmidt M, Sinn B, Klutinus N, Stickeler E, Untch M, Seiler S, Burchardi N, von Minckwitz G, Loibl S. Pharmacokinetic results of a subcutaneous injection of trastuzumab into the thigh versus into the abdominal wall in patients with HER2-positive primary breast cancer (BC) treated within the neo-/adjuvant GAIN-2 study [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-20-09.
Collapse
Affiliation(s)
- V Möbus
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - R Mahlberg
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - W Janni
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - O Tomé
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - F Marmé
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - H Forstbauer
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - T Reimer
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - A von der Assen
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - M Reinisch
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - R Lorenz
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - S Schmatloch
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - M Schmidt
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - B Sinn
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - N Klutinus
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - E Stickeler
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - M Untch
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - S Seiler
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - N Burchardi
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - G von Minckwitz
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - S Loibl
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| |
Collapse
|
17
|
Sinn BV, Weber K, Denkert C, Fasching PA, Schmitt WD, Thomas K, Ingold-Heppner B, van Mackelenbergh M, Symmans WF, Marmé F, Taube E, Müller V, Kunze CA, Schem C, Pfitzner BM, Stickeler E, von Minckwitz G, Loibl S. Abstract P1-07-01: HLA class I expression is associated with tumor-infiltrating lymphocytes and response and survival after neoadjuvant chemotherapy in hormone receptor-positive, HER2-negative breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-07-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Interactions between cancer cells and the host immune system influence tumor biology, response to therapy and patient survival and their modulation offers promising new approaches for cancer therapy. The downregulation or loss of HLA class I expression in breast cancer cells might be an effective mechanism to evade the recognition by the immune system facilitating malignant behavior.
Aim: To evaluate the association of tumor-infiltrating lymphocytes (TILs) with HLA class I expression and its theranostic value for therapy response and survival after neoadjuvant chemotherapy.
Methods: HLA class I expression was evaluated by immunohistochemistry in a cohort of 732 pre-therapeutic core biopsies from breast cancer patients treated within the neoadjuvant GeparTrio trial. Patients received anthracycline- and taxane-based neoadjuvant therapy and adjuvant endocrine treatment if hormone receptor-positive (HR+). A publicly available microarray dataset of pre-therapeutic core biopsies from 508 breast cancer patients that received neoadjuvant chemotherapy and endocrine treatment if HR+ was used for validation of the results. The association of HLA class I expression with predefined genomic signatures for immune cell populations was evaluated in publicly available data from the cancer genome atlas.
Results: HLA class I expression was associated with TILs (p < 0.001) and was predictive of better response to neoadjuvant chemotherapy in the subgroup of patients with HR+/HER2- breast cancer (14 % in tumors with high HLA vs. 7 % in tumors with low HLA, p = 0.029). Interestingly, high HLA was also predictive for shorter progression-free survival in univariate analysis (HR 1.590, 95 % CI 1.062—2.380; p = 0.024) and after adjustment to clinical and pathological parameters (HR 1.701, 95 % CI 1.105—2.618; p = 0.016). The results could be validated in the independent microarray-based dataset (HR 1.521, 95% CI 1.088 – 2.129; p = 0.0142). HLA class I was not associated with therapy response or survival in hormone receptor-negative breast cancer. HLA class I was associated with a predefined signature for T-cells and cytotoxic T- cells in the cancer genome atlas dataset (rho = 0.546).
Conclusion: HLA class I expression is associated with better response but shorter progression-free survival in HR+/HER2- breast cancer following neoadjuvant chemotherapy. The underlying mechanisms warrant further investigation.
Citation Format: Sinn BV, Weber K, Denkert C, Fasching PA, Schmitt WD, Thomas K, Ingold-Heppner B, van Mackelenbergh M, Symmans WF, Marmé F, Taube E, Müller V, Kunze CA, Schem C, Pfitzner BM, Stickeler E, von Minckwitz G, Loibl S. HLA class I expression is associated with tumor-infiltrating lymphocytes and response and survival after neoadjuvant chemotherapy in hormone receptor-positive, HER2-negative breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-07-01.
Collapse
Affiliation(s)
- BV Sinn
- Charité – Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany; German Breast Group Forschungs GmbH, Neu-Isenburg, Germany; University Hospital Erlangen, Erlangen, Germany; University Hospital Frankfurt, Frankfurt, Germany; University Hospital Schleswig-Holstein, Kiel, Germany; The University of Texas – MD Anderson Cancer Center, Houston, TX; University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; RWTH Aachen, Aachen, Aachen, Germany
| | - K Weber
- Charité – Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany; German Breast Group Forschungs GmbH, Neu-Isenburg, Germany; University Hospital Erlangen, Erlangen, Germany; University Hospital Frankfurt, Frankfurt, Germany; University Hospital Schleswig-Holstein, Kiel, Germany; The University of Texas – MD Anderson Cancer Center, Houston, TX; University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; RWTH Aachen, Aachen, Aachen, Germany
| | - C Denkert
- Charité – Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany; German Breast Group Forschungs GmbH, Neu-Isenburg, Germany; University Hospital Erlangen, Erlangen, Germany; University Hospital Frankfurt, Frankfurt, Germany; University Hospital Schleswig-Holstein, Kiel, Germany; The University of Texas – MD Anderson Cancer Center, Houston, TX; University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; RWTH Aachen, Aachen, Aachen, Germany
| | - PA Fasching
- Charité – Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany; German Breast Group Forschungs GmbH, Neu-Isenburg, Germany; University Hospital Erlangen, Erlangen, Germany; University Hospital Frankfurt, Frankfurt, Germany; University Hospital Schleswig-Holstein, Kiel, Germany; The University of Texas – MD Anderson Cancer Center, Houston, TX; University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; RWTH Aachen, Aachen, Aachen, Germany
| | - WD Schmitt
- Charité – Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany; German Breast Group Forschungs GmbH, Neu-Isenburg, Germany; University Hospital Erlangen, Erlangen, Germany; University Hospital Frankfurt, Frankfurt, Germany; University Hospital Schleswig-Holstein, Kiel, Germany; The University of Texas – MD Anderson Cancer Center, Houston, TX; University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; RWTH Aachen, Aachen, Aachen, Germany
| | - K Thomas
- Charité – Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany; German Breast Group Forschungs GmbH, Neu-Isenburg, Germany; University Hospital Erlangen, Erlangen, Germany; University Hospital Frankfurt, Frankfurt, Germany; University Hospital Schleswig-Holstein, Kiel, Germany; The University of Texas – MD Anderson Cancer Center, Houston, TX; University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; RWTH Aachen, Aachen, Aachen, Germany
| | - B Ingold-Heppner
- Charité – Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany; German Breast Group Forschungs GmbH, Neu-Isenburg, Germany; University Hospital Erlangen, Erlangen, Germany; University Hospital Frankfurt, Frankfurt, Germany; University Hospital Schleswig-Holstein, Kiel, Germany; The University of Texas – MD Anderson Cancer Center, Houston, TX; University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; RWTH Aachen, Aachen, Aachen, Germany
| | - M van Mackelenbergh
- Charité – Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany; German Breast Group Forschungs GmbH, Neu-Isenburg, Germany; University Hospital Erlangen, Erlangen, Germany; University Hospital Frankfurt, Frankfurt, Germany; University Hospital Schleswig-Holstein, Kiel, Germany; The University of Texas – MD Anderson Cancer Center, Houston, TX; University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; RWTH Aachen, Aachen, Aachen, Germany
| | - WF Symmans
- Charité – Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany; German Breast Group Forschungs GmbH, Neu-Isenburg, Germany; University Hospital Erlangen, Erlangen, Germany; University Hospital Frankfurt, Frankfurt, Germany; University Hospital Schleswig-Holstein, Kiel, Germany; The University of Texas – MD Anderson Cancer Center, Houston, TX; University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; RWTH Aachen, Aachen, Aachen, Germany
| | - F Marmé
- Charité – Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany; German Breast Group Forschungs GmbH, Neu-Isenburg, Germany; University Hospital Erlangen, Erlangen, Germany; University Hospital Frankfurt, Frankfurt, Germany; University Hospital Schleswig-Holstein, Kiel, Germany; The University of Texas – MD Anderson Cancer Center, Houston, TX; University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; RWTH Aachen, Aachen, Aachen, Germany
| | - E Taube
- Charité – Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany; German Breast Group Forschungs GmbH, Neu-Isenburg, Germany; University Hospital Erlangen, Erlangen, Germany; University Hospital Frankfurt, Frankfurt, Germany; University Hospital Schleswig-Holstein, Kiel, Germany; The University of Texas – MD Anderson Cancer Center, Houston, TX; University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; RWTH Aachen, Aachen, Aachen, Germany
| | - V Müller
- Charité – Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany; German Breast Group Forschungs GmbH, Neu-Isenburg, Germany; University Hospital Erlangen, Erlangen, Germany; University Hospital Frankfurt, Frankfurt, Germany; University Hospital Schleswig-Holstein, Kiel, Germany; The University of Texas – MD Anderson Cancer Center, Houston, TX; University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; RWTH Aachen, Aachen, Aachen, Germany
| | - CA Kunze
- Charité – Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany; German Breast Group Forschungs GmbH, Neu-Isenburg, Germany; University Hospital Erlangen, Erlangen, Germany; University Hospital Frankfurt, Frankfurt, Germany; University Hospital Schleswig-Holstein, Kiel, Germany; The University of Texas – MD Anderson Cancer Center, Houston, TX; University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; RWTH Aachen, Aachen, Aachen, Germany
| | - C Schem
- Charité – Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany; German Breast Group Forschungs GmbH, Neu-Isenburg, Germany; University Hospital Erlangen, Erlangen, Germany; University Hospital Frankfurt, Frankfurt, Germany; University Hospital Schleswig-Holstein, Kiel, Germany; The University of Texas – MD Anderson Cancer Center, Houston, TX; University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; RWTH Aachen, Aachen, Aachen, Germany
| | - BM Pfitzner
- Charité – Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany; German Breast Group Forschungs GmbH, Neu-Isenburg, Germany; University Hospital Erlangen, Erlangen, Germany; University Hospital Frankfurt, Frankfurt, Germany; University Hospital Schleswig-Holstein, Kiel, Germany; The University of Texas – MD Anderson Cancer Center, Houston, TX; University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; RWTH Aachen, Aachen, Aachen, Germany
| | - E Stickeler
- Charité – Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany; German Breast Group Forschungs GmbH, Neu-Isenburg, Germany; University Hospital Erlangen, Erlangen, Germany; University Hospital Frankfurt, Frankfurt, Germany; University Hospital Schleswig-Holstein, Kiel, Germany; The University of Texas – MD Anderson Cancer Center, Houston, TX; University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; RWTH Aachen, Aachen, Aachen, Germany
| | - G von Minckwitz
- Charité – Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany; German Breast Group Forschungs GmbH, Neu-Isenburg, Germany; University Hospital Erlangen, Erlangen, Germany; University Hospital Frankfurt, Frankfurt, Germany; University Hospital Schleswig-Holstein, Kiel, Germany; The University of Texas – MD Anderson Cancer Center, Houston, TX; University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; RWTH Aachen, Aachen, Aachen, Germany
| | - S Loibl
- Charité – Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany; German Breast Group Forschungs GmbH, Neu-Isenburg, Germany; University Hospital Erlangen, Erlangen, Germany; University Hospital Frankfurt, Frankfurt, Germany; University Hospital Schleswig-Holstein, Kiel, Germany; The University of Texas – MD Anderson Cancer Center, Houston, TX; University Hospital Heidelberg, Heidelberg, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; RWTH Aachen, Aachen, Aachen, Germany
| |
Collapse
|
18
|
Criscitiello C, Bayar M, Curigliano G, Symmans F, Desmedt C, Bonnefoi H, Sinn B, Pruneri G, Vicier C, Pierga J, Denkert C, Loibl S, Sotiriou C, Michiels S, André F. A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. Ann Oncol 2018; 29:162-169. [DOI: 10.1093/annonc/mdx691] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
|
19
|
Sinn M, Sinn BV, Striefler JK, Lindner JL, Stieler JM, Lohneis P, Bischoff S, Bläker H, Pelzer U, Bahra M, Dietel M, Dörken B, Oettle H, Riess H, Denkert C. SPARC expression in resected pancreatic cancer patients treated with Gemcitabine: results from the CONKO-001 study. Ann Oncol 2017; 28:2900. [PMID: 27578776 DOI: 10.1093/annonc/mdw269] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Criscitiello C, Bayar M, Curigliano G, Symmans F, Desmedt C, Bonnefoi H, Sinn B, Pruneri G, Vicier C, Pierga JY, Denkert C, Loibl S, Sotiriou C, Michiels S, André F. A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with anthracycline-based neoadjuvant chemotherapy. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx364] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Sinn M, Budczies J, Damm F, Lohneis P, Schmuck R, Treue D, Striefler J, Bahra M, Pelzer U, Jühling A, Bläker H, Bischoff S, Oettle H, Denkert C, Riess H, Sinn B. TP53 mutation predicts sensitivity to adjuvant gemcitabine in pancreatic cancer: Results from the CONKO-001 study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.120] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Sinn BV, Tsai TH, Lau R, Fu C, Gould R, Murthy R, King TA, Hatzis C, Kwiatkowski DN, Valero V, Symmans WF. Abstract P6-09-23: SETER/PR - A robust 18-gene predictor of sensitivity to endocrine therapy in metastatic breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-09-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Rationale: A robust index for gene expression related to activity of estrogen (ESR1) and progesterone (PGR) receptors could predict sensitivity to endocrine therapy in metastatic breast cancer.
Methods: Transcripts correlated with ESR1 and PGR expression in 389 hormone receptor-positive breast cancer samples (Affymetrix U133A microarrays) were ranked for reliability according to their pre-analytical (intratumoral heterogeneity, biopsy type) and analytical reproducibility. Eighteen target and ten reference genes were selected and summarized as the SETER/PR index. The SETER/PR index was evaluated in a different set of 140 biopsies from distant metastases of hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer, and in additional pre-analytical and analytical sample cohorts. Thereafter, SETER/PR was translated to a customized format for application to formalin-fixed and paraffin-embedded (FFPE) sections.
Results: Higher SETER/PR in a metastasis was associated with longer progression-free survival (PFS, 9 vs. 2 months) and overall survival (OS, 50 vs. 19 months) following endocrine therapy in the cohort with metastatic breast cancer (MBC) and relapsed disease (n=79), so a cut point was defined in that cohort. SETER/PR was also significantly associated with PFS after adjusting for PR status of the metastasis, presence of visceral metastases, number of previous relapse events, and clinical history of previous sensitivity to endocrine therapy (HR 0.485, 95%CI 0.265 – 0.889, p = 0.019). Technically, SETER/PR was highly reproducible under different pre-analytical and analytical conditions, including host organ contamination. The translated SETER/PR assay used a single 10 µm FFPE tissue section, did not require RNA purification, and represented the microarray results from matched fresh samples with excellent agreement (correlation = 0.980, n = 31).
Conclusion: The SETER/PR index is a new biomarker to predict PFS and OS for patients with HR+/HER2- MBC who receive endocrine therapy. The assay is applicable to FFPE tissue sections from small biopsies of metastases. Additional independent (blinded) validation studies will be necessary to confirm these results.Rationale: A robust index for gene expression related to activity of estrogen (ESR1) and progesterone (PGR) receptors could predict sensitivity to endocrine therapy in metastatic breast cancer.
Methods: Transcripts correlated with ESR1 and PGR expression in 389 hormone receptor-positive breast cancer samples (Affymetrix U133A microarrays) were ranked for reliability according to their pre-analytical (intratumoral heterogeneity, biopsy type) and analytical reproducibility. Eighteen target and ten reference genes were selected and summarized as the SETER/PR index. The SETER/PR index was evaluated in a different set of 140 biopsies from distant metastases of hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer, and in additional pre-analytical and analytical sample cohorts. Thereafter, SETER/PR was translated to a customized format for application to formalin-fixed and paraffin-embedded (FFPE) sections.
Results: Higher SETER/PR in a metastasis was associated with longer progression-free survival (PFS, 9 vs. 2 months) and overall survival (OS, 50 vs. 19 months) following endocrine therapy in the cohort with metastatic breast cancer (MBC) and relapsed disease (n=79), so a cut point was defined in that cohort. SETER/PR was also significantly associated with PFS after adjusting for PR status of the metastasis, presence of visceral metastases, number of previous relapse events, and clinical history of previous sensitivity to endocrine therapy (HR 0.485, 95%CI 0.265 – 0.889, p = 0.019). Technically, SETER/PR was highly reproducible under different pre-analytical and analytical conditions, including host organ contamination. The translated SETER/PR assay used a single 10 µm FFPE tissue section, did not require RNA purification, and represented the microarray results from matched fresh samples with excellent agreement (correlation = 0.980, n = 31).
Conclusion: The SETER/PR index is a new biomarker to predict PFS and OS for patients with HR+/HER2- MBC who receive endocrine therapy. The assay is applicable to FFPE tissue sections from small biopsies of metastases. Additional independent (blinded) validation studies will be necessary to confirm these results.
Citation Format: Sinn BV, Tsai T-H, Lau R, Fu C, Gould R, Murthy R, King TA, Hatzis C, Kwiatkowski DN, Valero V, Symmans WF. SETER/PR - A robust 18-gene predictor of sensitivity to endocrine therapy in metastatic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-09-23.
Collapse
Affiliation(s)
- BV Sinn
- The University of Texas MD Anderson Cancer Center, Houston, TX; Brigham and Women's / Dana Farber Cancer Center, Boston, MA; Section of Breast Medical Oncology, Yale School of Medicine, Yale Cancer Center, New Haven, CT; Charité Universitätsmedizin Berlin, Berlin, Germany
| | - T-H Tsai
- The University of Texas MD Anderson Cancer Center, Houston, TX; Brigham and Women's / Dana Farber Cancer Center, Boston, MA; Section of Breast Medical Oncology, Yale School of Medicine, Yale Cancer Center, New Haven, CT; Charité Universitätsmedizin Berlin, Berlin, Germany
| | - R Lau
- The University of Texas MD Anderson Cancer Center, Houston, TX; Brigham and Women's / Dana Farber Cancer Center, Boston, MA; Section of Breast Medical Oncology, Yale School of Medicine, Yale Cancer Center, New Haven, CT; Charité Universitätsmedizin Berlin, Berlin, Germany
| | - C Fu
- The University of Texas MD Anderson Cancer Center, Houston, TX; Brigham and Women's / Dana Farber Cancer Center, Boston, MA; Section of Breast Medical Oncology, Yale School of Medicine, Yale Cancer Center, New Haven, CT; Charité Universitätsmedizin Berlin, Berlin, Germany
| | - R Gould
- The University of Texas MD Anderson Cancer Center, Houston, TX; Brigham and Women's / Dana Farber Cancer Center, Boston, MA; Section of Breast Medical Oncology, Yale School of Medicine, Yale Cancer Center, New Haven, CT; Charité Universitätsmedizin Berlin, Berlin, Germany
| | - R Murthy
- The University of Texas MD Anderson Cancer Center, Houston, TX; Brigham and Women's / Dana Farber Cancer Center, Boston, MA; Section of Breast Medical Oncology, Yale School of Medicine, Yale Cancer Center, New Haven, CT; Charité Universitätsmedizin Berlin, Berlin, Germany
| | - TA King
- The University of Texas MD Anderson Cancer Center, Houston, TX; Brigham and Women's / Dana Farber Cancer Center, Boston, MA; Section of Breast Medical Oncology, Yale School of Medicine, Yale Cancer Center, New Haven, CT; Charité Universitätsmedizin Berlin, Berlin, Germany
| | - C Hatzis
- The University of Texas MD Anderson Cancer Center, Houston, TX; Brigham and Women's / Dana Farber Cancer Center, Boston, MA; Section of Breast Medical Oncology, Yale School of Medicine, Yale Cancer Center, New Haven, CT; Charité Universitätsmedizin Berlin, Berlin, Germany
| | - DN Kwiatkowski
- The University of Texas MD Anderson Cancer Center, Houston, TX; Brigham and Women's / Dana Farber Cancer Center, Boston, MA; Section of Breast Medical Oncology, Yale School of Medicine, Yale Cancer Center, New Haven, CT; Charité Universitätsmedizin Berlin, Berlin, Germany
| | - V Valero
- The University of Texas MD Anderson Cancer Center, Houston, TX; Brigham and Women's / Dana Farber Cancer Center, Boston, MA; Section of Breast Medical Oncology, Yale School of Medicine, Yale Cancer Center, New Haven, CT; Charité Universitätsmedizin Berlin, Berlin, Germany
| | - WF Symmans
- The University of Texas MD Anderson Cancer Center, Houston, TX; Brigham and Women's / Dana Farber Cancer Center, Boston, MA; Section of Breast Medical Oncology, Yale School of Medicine, Yale Cancer Center, New Haven, CT; Charité Universitätsmedizin Berlin, Berlin, Germany
| |
Collapse
|
23
|
Sinn M, Riess H, Sinn BV, Stieler JM, Pelzer U, Striefler JK, Oettle H, Bahra M, Denkert C, Bläker H, Lohneis P. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial. Eur J Cancer 2015; 51:1546-54. [PMID: 26049689 DOI: 10.1016/j.ejca.2015.05.005] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2015] [Revised: 04/25/2015] [Accepted: 05/05/2015] [Indexed: 02/07/2023]
Abstract
BACKGROUND High expression of human equilibrative nucleoside transporter 1 (hENT1) is considered to predict survival in patients treated with adjuvant gemcitabine for pancreatic cancer. A standard evaluation system for immunohistochemical analysis (antibody, scoring system) has not yet been established. METHODS CONKO-001, a prospective randomised phase III study investigated the role of adjuvant gemcitabine (gem) as compared to observation (obs). Tumour samples of 156 patients were analysed by immunohistochemistry with the rabbit monoclonal antibody SP120 (Ventana Medical Systems) for expression of hENT1. Kaplan-Meier analyses for median disease-free survival (DFS) and overall survival (OS) were performed in dependence of hENT1 expression measured analogously to Farrell et al. 2009 and Poplin et al. 2013. RESULTS For the 88 gem and 68 obs patients, median DFS/OS was 12.9/22.7 months and 6.2/19.1 months. High hENT1 expression was not associated with improved median DFS (Farrell: no hENT1 22.2 months, low hENT1 13.7 months, high hENT1 12.1 months, p=0.248; Poplin: low hENT1 13.2 months versus high hENT1 11.5 months, p=0.5) or median OS (Farrell: no hENT1 21.7 months, low hENT1 24.7 months, high hENT1 19.5, p=0.571; Poplin: low hENT1 24.4 months versus high hENT1 19.7 months, p=0.92;) in the gem group or in the obs group (median DFS Farrell: no hENT1 5.1 months, low hENT1 6.2 months, high hENT1 7.5 months, p=0.375; Poplin: low hENT1 6.2 months versus high hENT1 5.9 months, p=0.83; median OS Farrell: no hENT1 20.2months, low hENT1 17.7 months, high HENT1 19.1 months, p=0.738; Poplin: low hENT1 17.7 months versus high hENT1 20.4 months, p=0.65) measured by the Farrell or Poplin Score. CONCLUSIONS We cannot confirm a predictive role of hENT1 measured by the clone SP120 rabbit antibody in our study population. Reproducible standard procedures are urgently needed prior to the implementation or exclusion of hENT1 as a predictive biomarker in the treatment of pancreatic cancer. TRIAL REGISTRATION ISRCTN34802808.
Collapse
Affiliation(s)
- M Sinn
- Charité - Universitätsmedizin Berlin, Department of Medical Oncology and Haematology, Augustenburger Platz 1, 13353 Berlin, Germany.
| | - H Riess
- Charité - Universitätsmedizin Berlin, Department of Medical Oncology and Haematology, Augustenburger Platz 1, 13353 Berlin, Germany
| | - B V Sinn
- Charité - Universitätsmedizin Berlin, Institute of Pathology, Charitéplatz 1, 10117 Berlin, Germany
| | - J M Stieler
- Charité - Universitätsmedizin Berlin, Department of Medical Oncology and Haematology, Augustenburger Platz 1, 13353 Berlin, Germany
| | - U Pelzer
- Charité - Universitätsmedizin Berlin, Department of Medical Oncology and Haematology, Augustenburger Platz 1, 13353 Berlin, Germany
| | - J K Striefler
- Charité - Universitätsmedizin Berlin, Department of Medical Oncology and Haematology, Augustenburger Platz 1, 13353 Berlin, Germany
| | - H Oettle
- Outpatient Department Hematology/Oncology, Friedrichstr. 53, 88045 Friedrichshafen, Germany
| | - M Bahra
- Charité - Universitätsmedizin Berlin, Department of General, Visceral and Transplantation Surgery, Augustenburger Platz 1, 13353 Berlin, Germany
| | - C Denkert
- Charité - Universitätsmedizin Berlin, Institute of Pathology, Charitéplatz 1, 10117 Berlin, Germany
| | - H Bläker
- Charité - Universitätsmedizin Berlin, Institute of Pathology, Charitéplatz 1, 10117 Berlin, Germany
| | - P Lohneis
- Charité - Universitätsmedizin Berlin, Institute of Pathology, Charitéplatz 1, 10117 Berlin, Germany
| |
Collapse
|
24
|
Lindner JL, Loibl S, Denkert C, Ataseven B, Fasching PA, Pfitzner BM, Gerber B, Gade S, Darb-Esfahani S, Sinn BV, Huober J, Engels K, Tesch H, Karn T, Pommerenke F, Liedtke C, Untch M, Müller V, Rack B, Schem C, von Minckwitz G. Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy. Ann Oncol 2015; 26:95-100. [PMID: 25355716 DOI: 10.1093/annonc/mdu487] [Citation(s) in RCA: 58] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Secreted protein acidic and rich in cysteine (SPARC) has been suggested as a new biomarker and therapeutic target in breast cancer, as well as other tumor types. PATIENTS AND METHODS We evaluated the frequency of SPARC expression among different molecular breast cancer subtypes and its role for therapy response after neoadjuvant chemotherapy. In this study, pretherapeutic core biopsies of 667 patients from the neoadjuvant GeparTrio trial were evaluated for SPARC expression by immunohistochemistry using a standardized immunoreactive score (IRS). RESULTS An increased SPARC expression (IRS ≥6) was observed in 26% of all tumors. In triple-negative tumors, SPARC expression was increased in 37% of tumors, compared with other molecular subtypes (23% HR+/HER2-, 29% HR+/HER2+ and 22% HR-/HER2+; P = 0.038). Increased SPARC expression was associated with an increased pathological complete response (pCR) rate of 27%, compared with 15% in tumors with low SPARC expression (P < 0.001). In the triple-negative subgroup, pCR rates were 47% in tumors with high SPARC expression, compared with 26% in tumors with low SPARC expression (P = 0.032). In multivariable analysis, SPARC was independently predictive in the overall population (P = 0.010) as well as the triple-negative subgroup (P = 0.036). CONCLUSIONS SPARC is frequently expressed in breast cancer with triple-negative breast cancer revealing the highest expression rate. High SPARC expression of the primary tumor is associated with a higher chance of achieving a pathological complete remission after TAC or TAC-NX chemotherapy. As SPARC is an albumin-binding protein and might mediate intratumoral accumulation of albumin bound drugs, SPARC should be further evaluated as a predictive marker especially for response to albumin-bound drugs like nab-paclitaxel. CLINICAL TRIAL NUMBER NCT00544765.
Collapse
Affiliation(s)
- J L Lindner
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin
| | - S Loibl
- German Breast Group, Neu-Isenburg; Department of Oncology, Klinikum Offenbach, Offenbach
| | - C Denkert
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin.
| | - B Ataseven
- Department of Gynecology, Kliniken-Essen-Mitte, Essen
| | - P A Fasching
- Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen
| | - B M Pfitzner
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin
| | - B Gerber
- Department of Gynecology, Klinikum Südstadt Rostock, Rostock
| | - S Gade
- German Breast Group, Neu-Isenburg
| | - S Darb-Esfahani
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin
| | - B V Sinn
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin
| | - J Huober
- Department of Obstetrics and Gynecology, Universitätsklinikum Ulm, Ulm
| | - K Engels
- Department of Pathology, Zentrum für Pathologie, Zytologie und Molekularpathologie, Neuss
| | - H Tesch
- Oncological Center, Bethanien-Hospital, Frankfurt am Main
| | - T Karn
- Department of Obstetrics and Gynecology, Goethe-Universität, Frankfurt/Main
| | - F Pommerenke
- Institute of Pathology, Klinikum Südstadt, Rostock
| | - C Liedtke
- Department of Obstetrics and Gynecology, Universitätsklinikum Schleswig-Holstein, Lübeck
| | - M Untch
- Department of Obstetrics and Gynecology, Helios Klinikum Berlin-Buch, Berlin
| | - V Müller
- Department of Gynecology, Universitätsklinikum Hamburg-Eppendorf, Hamburg
| | - B Rack
- Department of Obstetrics and Gynecology, Ludwig-Maximilians-Universität München, München
| | - C Schem
- Department of Obstetrics and Gynecology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - G von Minckwitz
- German Breast Group, Neu-Isenburg; Department of Obstetrics and Gynecology, Goethe-Universität, Frankfurt/Main
| |
Collapse
|
25
|
Sinn M, Sinn BV, Striefler JK, Lindner JL, Stieler JM, Lohneis P, Bischoff S, Bläker H, Pelzer U, Bahra M, Dietel M, Dörken B, Oettle H, Riess H, Denkert C. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Ann Oncol 2014; 25:1025-32. [PMID: 24562449 DOI: 10.1093/annonc/mdu084] [Citation(s) in RCA: 65] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND Previous investigations in pancreatic cancer suggested a prognostic role for secreted protein acidic and rich in cysteine (SPARC) expression in the peritumoral stroma but not for cytoplasmic SPARC expression. The aim of this study was to evaluate the impact of SPARC expression in pancreatic cancer patients treated with gemcitabine compared with untreated patients. PATIENTS AND METHODS CONKO-001 was a prospective randomized phase III study investigating the role of adjuvant gemcitabine when compared with observation. Tissue samples of 160 patients were available for SPARC immunohistochemistry on tissue microarrays to evaluate its impact on patient outcome. RESULTS Strong stromal SPARC expression was associated with worse disease-free survival (DFS) and overall survival (OS) in the overall study population (DFS: P = 0.005, OS: P = 0.033). Its negative prognostic impact was restricted to patients treated with gemcitabine (DFS: P = 0.007, OS: P = 0.006). High cytoplasmic SPARC expression also was associated with worse patient outcome (DFS: P = 0.041, OS: P = 0.011). Again the effect was restricted to patients treated with gemcitabine (DFS: P = 0.002, OS: P = 0.003). In multivariable analysis, SPARC expression was independently predictive of patient outcome. CONCLUSIONS Our data confirm the prognostic significance of SPARC expression after curatively intended resection. The negative prognostic impact was restricted to patients who received adjuvant treatment with gemcitabine, suggesting SPARC as a predictive marker for response to gemcitabine.
Collapse
Affiliation(s)
- M Sinn
- Department of Medical Oncology and Haematology
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Sinn BV, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Tesch H, Kronenwett R, Hoffmann G, Belau A, Thommsen C, Holzhausen HJ, Grasshoff ST, Baumann K, Mehta K, Dietel M, Loibl S. Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer. Ann Oncol 2013; 24:2316-24. [PMID: 23661292 DOI: 10.1093/annonc/mdt162] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
BACKGROUND Mucin-1 (MUC1) is a promising antigen for the development of tumor vaccines. We evaluated the frequency of MUC1 expression and its impact on therapy response and survival after neoadjuvant chemotherapy for breast cancer. PATIENTS AND METHODS Pre-treatment core biopsies of patients from the GeparTrio neoadjuvant trial (NCT 00544765) were evaluated for MUC1 by immunohistochemistry (IHC; N = 691) and quantitative RT-PCR (qRT-PCR; N = 286) from formalin-fixed paraffin-embedded (FFPE) samples. RESULTS MUC1 protein and mRNA was detectable in the majority of cases and was associated with hormone-receptor-positive status (P < 0.001). High MUC1 protein and mRNA expression were associated with lower probability of pathologic complete response (P = 0.017 and P < 0.001) and with longer patient survival (P = 0.03 and P < 0.001). In multivariable analysis, MUC1 protein and mRNA expression were independently predictive (P = 0.001 and P < 0.001). MUC1 protein and mRNA expression were independently prognostic for overall survival (P = 0.029 and P = 0.015). CONCLUSIONS MUC1 is frequently expressed in breast cancer and detectable on mRNA and protein level from FFPE tissue. It provides independent predictive information for therapy response and survival after neoadjuvant chemotherapy. In clinical immunotherapy trials, MUC1 expression may serve as a predictive marker.
Collapse
Affiliation(s)
- B V Sinn
- Department of Pathology, Charité-Universitätsmedizin Berlin, Berlin.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Denecke T, Seidensticker R, Sinn B, Puhl G, Schott E, Gebauer B, Lopez Hänninen E, Wust P, Hamm B, Neuhaus P, Seehofer D. CT-gestützte Brachytherapie von hepatozellulären Karzinomen als Bridging-Option vor Lebertransplantation. ROFO-FORTSCHR RONTG 2012. [DOI: 10.1055/s-0032-1311269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
28
|
Denkert C, Kronenwett R, Loibl S, Nekljudova V, Darb-Esfahani S, Gerber B, Sinn B, Petry C, Bauerfeind I, Budczies J, Rezai M, Dietel M, Schrader I, Kunz G, Von Minckwitz G. RNA-based molecular tumor typing and immunological infiltrate as response predictors to neoadjuvant chemotherapy: Prospective validation in the GeparQuinto-PREDICT substudy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10526] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Heitz F, Sinn B, Loibl S, Du Bois A, Jackisch C, Kuemmel S, Denkert C, Barinoff J, Mehta K, Von Minckwitz G. Effect of estrogen receptor beta expression (ERße) in triple-negative breast cancer (TNBC) patients treated in the neoadjuvant GeparTrio trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Zamagni C, Wirtz RM, Sinn B, De Iaco P, Darb-Esfahani S, Rosati M, Dietel M, Massari F, Martoni AA, Denkert C. Estrogen receptor 1 mRNA expression as a strong prognostic factor in epithelial ovarian cancer patients treated with chemotherapy in the adjuvant and neoadjuvant setting. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.16547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
31
|
Niesporek S, Weichert W, Sinn B, Röske A, Noske A, Buckendahl AC, Wirtz R, Sehouli J, Koensgen D, Dietel M, Denkert C. [NF-kappaB subunit p65/RelA expression in ovarian carcinoma: prognostic impact and link to COX-2 overexpression]. Verh Dtsch Ges Pathol 2007; 91:243-249. [PMID: 18314621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
AIMS NF-kappaB has been demonstrated to activate proliferative, inflammatory, and angiogenic processes in ovarian cancer cells in vitro. To add translational information on the situation in vivo, we determined the expression pattern of p65, an important subunit of the classic NF-kappaB pathway, in ovarian carcinoma tissue, and investigated in vivo and in vitro whether this pathway is implicated in the known overexpression of cyclooxygenase-2 (COX-2). METHODS p65 siRNA, chemiluminescent NF-kappaB transcription factor assay, Taqman PCR, as well as immunoblotting were performed with OVCAR-3 ovarian cancer cells. 83 primary ovarian cancinomas as well as 17 cases of benign ovarian tissue were analyzed by p65 and COX-2 immunohistochemistry using a tissue microarray. RESULTS DNA-binding avtivity as well as COX-2 mRNA and protein expression were strongly inducible by IL-1beta treatment in OVCAR-3 cells, while p65 siRNA inhibited IL-1beta-dependent p65 activity (p = 0.037) as well as COX-2 expression on the mRNA (p < 0.03) and on the protein level. In human tumor tissue, p65 protein expression was significantly associated with COX-2 expression (p = 0.002) as well as tumor grading (p = 0.005). Furthermore, p65 expression was a significant prognostic indicator of a reduced patient survival both in univariate (p = 0.038) and in multivariate analysis (p = 0.014). CONCLUSION Our study indicates a deregulation of the classical NF-kappaB pathway in ovarian cancer, which results in the overexpression of the NF-kappaB target gene COX-2. Components of this pathway might constitute novel attractive targets for a specific therapy of advanced ovarian cancer.
Collapse
Affiliation(s)
- S Niesporek
- Institut für Pathologie, Charité-Universitätsmedizin Berlin, Campus Mitte
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Stuschke M, Sak A, Wurm R, Sinn B, Wolf G, Stüben G, Budach V. Radiation-induced apoptosis in human non-small-cell lung cancer cell lines is secondary to cell-cycle progression beyond the G2-phase checkpoint. Int J Radiat Biol 2002; 78:807-19. [PMID: 12428922 DOI: 10.1080/09553000210148903] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
PURPOSE To characterize the relationship between cell-cycle progression and radiation-induced apoptosis in NSCLC cell lines with different p53 status. MATERIALS AND METHODS Cell lines with functional (H460, A549) and non-functional p53 (H661 and H520) were irradiated with 20 Gy. Multiparameter flow-cytometry was used to follow the progression of synchronized cells through the cell cycle after irradiation. RESULTS Delayed apoptosis was observed after cell-cycle progression beyond the G2 block, either in the late G2/M-phase of the same cell cycle being irradiated (H661, H520) or in the G1-phase of the subsequent cell cycle (H460, A549). The apoptotic fraction in H661 and H520 was 60-80% at 144h after irradiation, higher than in A549 and H460 (5 and 35%, respectively). As an alternative to apoptosis in cells cycling beyond the G2 restriction point, hyperploid cells were generated by all cell lines. Inhibition of cell-cycle progression through the G2/M-phase efficiently reduced the induction of late apoptosis. After irradiation in S-phase, 50-60% of cells with functional p53 remained arrested at the G2 restriction point until 144 h post-irradiation, while only 20% of the H661 or H520 did so. CONCLUSIONS These data characterize radiation-induced apoptosis in NSCLC cell lines as a removal pathway of clonogenically inactivated cells secondary to cell-cycle progression beyond G2/M, and is unlikely to be a critical factor for cellular radiation sensitivity.
Collapse
Affiliation(s)
- M Stuschke
- Department of Radiotherapy, Humboldt-University, Charité, Berlin, Germany.
| | | | | | | | | | | | | |
Collapse
|
33
|
Mangoldt D, Sinn B, Lein M, Krell HW, Schnorr D, Loening SA, Jung K. The novel synthetic inhibitor of matrix metalloproteinases Ro 28-2653 induces apoptosis in Dunning tumor cells. Apoptosis 2002; 7:217-20. [PMID: 11997665 DOI: 10.1023/a:1015383231080] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The effect of synthetic inhibitors of matrix metalloproteinases (MMP) has been shown against a variety of tumors in preclinical models. Ro 28-2653, a novel synthetic MMP inhibitor, is able to reduce tumor growth in orthotopic prostatic cancer in rats (R3327 Dunning tumor). However, at present this inhibitory mechanism in tumor inhibition in vivo can only be partly explained by the inhibition of the catalytic activity of MMPs overexpressed in cancereous tissue. Using the flow cytometric method, we have investigated the effect of various concentrations of Ro 28-2653 on the Dunning tumor cells with regard to the staining of F-actin and DNA as markers of apoptosis. In combination with fluorescence microscopy we detected the loss of F-actin and the degradation of internucleosomal DNA. This effect of Ro 28-2653 on apoptosis was dose- and time-dependent increasing with concentration between 10 and 100 microg/ml as well as with time of treatment between 24 and 48 h.
Collapse
Affiliation(s)
- D Mangoldt
- Department of Urology, University Hospital Charité, Humboldt University, Berlin, Germany
| | | | | | | | | | | | | |
Collapse
|
34
|
Middelboe M, Hagström A, Blackburn N, Sinn B, Fischer U, Borch N, Pinhassi J, Simu K, Lorenz M. Effects of Bacteriophages on the Population Dynamics of Four Strains of Pelagic Marine Bacteria. Microb Ecol 2001; 42:395-406. [PMID: 12024264 DOI: 10.1007/s00248-001-0012-1] [Citation(s) in RCA: 74] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Viral lysis of specific bacterial populations has been suggested to be an important factor for structuring marine bacterioplankton communities. In the present study, the influence of bacteriophages on the diversity and population dynamics of four marine bacterial phage-host systems was studied experimentally in continuous cultures and theoretically by a mathematical model. By use of whole genome DNA hybridization toward community DNA, we analyzed the dynamics of individual bacterial host populations in response to the addition of their specific phage in continuous cultures of mixed bacterial assemblages. In these experiments, viral lysis had only temporary effects on the dynamics and diversity of the individual bacterial host species. Following the initial lysis of sensitive host cells, growth of phage-resistant clones of the added bacteria resulted in a distribution of bacterial strains in the phage-enriched culture that was similar to that in the control culture without phages after about 50-60 h incubation. Consequently, after a time frame of 5-10 generations after lysis, it was the interspecies competition rather than viral lysis of specific bacterial strains that was the driving force in the regulation of bacterial species composition in these experiments. The clonal diversity, on the other hand, was strongly influenced by viral activity, since the clonal composition of the four species in the phage-enriched culture changed completely from phage-sensitive to phage-resistant clones. The model simulation predicted that viral lysis had a strong impact on the population dynamics, the species composition, and the clonal composition of the bacterial community over longer time scales (weeks). However, according to the model, the overall density of bacteria in the system was not affected by phages, since resistant clones complemented the fluctuations caused by viral lysis. Based on the model analysis, we therefore suggest that viral lysis can have a strong influence on the dynamics of bacterial populations in planktonic marine systems.
Collapse
Affiliation(s)
- M. Middelboe
- Marine Biological Laboratory, University of Copenhagen, Strandpromenaden 5, DK-3000 Helsingør, Denmark
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Kruse FE, Joussen AM, Rohrschneider K, You L, Sinn B, Baumann J, Völcker HE. Cryopreserved human amniotic membrane for ocular surface reconstruction. Graefes Arch Clin Exp Ophthalmol 2000; 238:68-75. [PMID: 10664056 DOI: 10.1007/s004170050012] [Citation(s) in RCA: 135] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
BACKGROUND Amniotic membrane transplantation is used for the reconstruction of the ocular surface in the context of, for example, corneal ulcers or conjunctival scarring. The mechanisms by which preserved amniotic membrane grafts promote reepithelialization are unknown. As a first step the viability and proliferative capacity of amnion cells following cryopreservation of membranes in glycerol is investigated. METHODS Fresh and cryopreserved (in 50% glycerol) amniotic membranes were investigated histologically and by vital stains. Following enzymatic digestion, amniotic cells were stained for viability and cultured in DMEM+10% FBS. In addition, explant cultures were established from fresh and cryopreserved membranes. RESULTS Histological examination showed no significant morphological alteration following cryopreservation. While fresh membranes contained predominantly vital cells, no such cells were detected following cryopreservation. Also, cells removed enzymatically from cryopreserved membranes were not viable and did not grow in culture. While both epithelial and fibroblastic cells grew from fresh membranes, no growth was seen from cryopreserved membranes. CONCLUSION The results suggest that the technique for preservation which is most widely used for ophthalmological amniotic membrane transplantation significantly impairs viability and proliferative capacity. This supports the clinical finding that neither immunological reactions nor signs of ingrowth of amniotic cells are observed in patients. Furthermore amniotic membrane grafts seem to function primarily as matrix and not by virtue of transplanted functional cells.
Collapse
Affiliation(s)
- F E Kruse
- Augenklinik der Universität Heidelberg, INF 400, D-69120 Heidelberg, Germany.
| | | | | | | | | | | | | |
Collapse
|
36
|
Berthe-Corti L, Conradi B, Hulsch R, Sinn B, Wiesehan K. Microbial cleaning of waste gas containing volatile organic compounds in a bioreactor system with a closed gas circuit. ACTA ACUST UNITED AC 1998. [DOI: 10.1002/abio.370180402] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
37
|
Schlenger L, Flath B, Sinn B, Budach V, Wurm A. Chromatin structure in human glioma cell lines with different radiosensitivity. Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)84484-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
38
|
Naundorf H, Parczyk K, Zschiesche W, Reinecke S, Büttner B, Saul GJ, Sinn B, Fichtner I. Relation of oestradiol-mediated growth stimulation with the expression of c-erbB-2 protein in xenotransplanted oestradiol-receptor-positive and -negative breast carcinomas. J Cancer Res Clin Oncol 1996; 122:14-20. [PMID: 8543587 DOI: 10.1007/bf01203068] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Attempts were made to correlate growth effects induced by oestradiol and tamoxifen with the hormonal regulation of c-erbB-2 protein in experiments in vivo. We report here the responsiveness of four xenotransplanted oestrogen-receptor(ER)-positive and four ER-negative human mammary carcinomas to oestradiol and tamoxifen. Oestradiol in a dose of 0.5 mg/kg significantly increased the growth of the ER-positive mammary carcinomas 3366, MCF-7, 4134 and 4049, but not the ER-negative tumours 4000, 4296 and MT-3. However, within the group of the ER-negative breast carcinomas the tumour 4151 ES deviates from this growth behaviour, as we could prove an estrogen induced growth. The stimulation of tumour growth by oestradiol was always accompanied by a down-regulation of c-erbB-2 protein both in the ER-positive mammary carcinomas and in the ER-negative mammary carcinoma 4151 ES. Tamoxifen significantly inhibited the growth of the ER/PR-positive mammary carcinomas 3366 and MCF-7 but not the ER-positive/PR-negative mammary carcinomas 4049 and 4134. In the group of ER-negative mammary carcinomas only the growth of the oestrogen-responsive tumour 4151 ES was significantly inhibited by tamoxifen. The inhibition of tumour growth by tamoxifen was correlated with a reversion of the oestradiol-induced down-regulation of c-erbB-2, also in the ER-negative/oestradiol-responsive mammary carcinoma 4151 ES. From our results we hypothesize that the oestrogen-dependent growth of ER-negative breast carcinoma 4151 ES could also be correlated with the oestradiol-regulated expression of c-erbB-2 protein.
Collapse
MESH Headings
- Animals
- Base Sequence
- Breast Neoplasms/drug therapy
- Breast Neoplasms/metabolism
- Breast Neoplasms/pathology
- DNA Primers/chemistry
- Estradiol/pharmacology
- Estrogen Antagonists/pharmacology
- Female
- Humans
- Mammary Neoplasms, Experimental/drug therapy
- Mammary Neoplasms, Experimental/metabolism
- Mammary Neoplasms, Experimental/pathology
- Mice
- Mice, Nude
- Molecular Sequence Data
- Neoplasm Transplantation
- Polymerase Chain Reaction
- RNA, Messenger/biosynthesis
- Receptor, ErbB-2/biosynthesis
- Receptors, Estradiol/metabolism
- Receptors, Progesterone/metabolism
- Tamoxifen/pharmacology
- Transplantation, Heterologous
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- H Naundorf
- Max-Delbrück-Centre for Molecular Medicine, Berlin, Germany
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Saul G, Sinn B, Rink B. [Estrogen receptor status in patients with oral mucosa carcinoma (a brief report)]. Stomatol DDR 1985; 35:146-8. [PMID: 3863326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|